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Over the last few decades, the field of chemical biology has been revolutionised by 
the advent of so-called bioorthogonal reactions – chemical transformations that can 
be performed in living systems.  They have emerged as a powerful tool in allowing 
the study of biomolecules such as proteins in their native environment. Among the 
plethora of bioorthogonal reactions, tetrazine chemistry is one of the most promising 
due to its fast reaction rates, high selectivity and compatibility, allowing its 
applications to span from imaging to drug delivery.  
One of the major concerns in drug activation, especially in cancer, is the lack of 
specificity of the administered drugs, causing horrible side-effects. The use of a 
selective transformation that would allow the activation of a toxic drug only at the 
specific target (such as a tumour) is highly desirable. Here tetrazine chemistry was 
investigated as a drug activation strategy, in order to deliver and activate toxic drugs 
selectively at the target site, with the vision of lowering off-target effects. 
The application of tetrazine chemistry was also investigated for imaging purposes. 
Some fluorescent techniques are used clinically to help surgeons to efficiently target 
tumour removal. However, one of the major challenges is to minimize the 
background fluorescence derived from non-cancerous tissue. Hence, in my work a 
technique that would help to amplify the fluorescence signals was developed. Thus 
a non-fluorescent tetrazine was synthesised and its reaction with a polymer 












Tetrazines are aromatic six-membered heterocycles, containing four nitrogen atoms 
that can react as dienes in inverse-electron-demand Diels–Alder (IEDDA) reactions 
leading to the formation of pyridazines. Owing to their high chemical selectivity, fast 
reactivity and biocompatibility, the IEDDA reaction between s-tetrazines and 
dienophiles has become a powerful tool in a variety of biological applications. Thus 
tetrazines have been exploited in applications ranging from nuclear medicine and 
imaging to drug delivery. The focus of my thesis has been on the design and the 
synthesis of new tetrazine scaffolds and their use in organic chemistry, drug 
activation and pre-targeting applications.  
In one area I successfully achieved the design and synthesis of a new orthogonal 
protecting group (vinyl ether benzyloxycarbonyl) that could be selectively cleaved by 
treatment with a tetrazine, resulting in a versatile protection strategy to temporarily 
mask amino functionalities in solid-phase peptide synthesis. The power of this 
approach was shown with the synthesis of two cyclic peptides, showing its 
orthogonality and compatibility with other protecting groups commonly used in 
Fmoc-based peptide chemistry.  
A new concept in drug activation chemistry was developed where tetrazines were 
used to design a fully traceless dual prodrug-prodrug activation strategy in which a 
tetrazine-masked drugs and a vinyl ether protected anti-cancer drug were co-
reacted via IEDDA chemistry to generate a pyridazine-based miRNA-21 inhibitor 
and the free anticancer drug camptothecin under biologically compatible conditions.  
Finally, in collaboration, an “amplification probe” was designed in which tetrazine-
quenched fluorophores were synthesized and used to give massive signal 
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Tetrazines are electron-deficient aromatic six-membered heterocycles containing 
four nitrogens. The tetrazine family covers three isomers, the 1,2,3,4-tetrazines, 
the 1,2,3,5-tetrazines, and the 1,2,4,5-tetrazines, the so-called s-tetrazines 
(symmetric) (Figure 1.1).1 The most investigated are the 1,2,4,5-tetrazines due to 
their higher stabilities and their peculiar reactivities.1 Their synthesis was first 
reported in the late 19th century by Pinner2 but their unique chemical and physical 
properties were discovered only in 1950s when Carboni and Lindsey3 reported their 
outstanding reactivity as dienes in inverse-electron-demand Diels–Alder (IEDDA) 
reactions with various unsaturated compounds (e.g. alkenes and alkynes), providing 
an attractive route to the synthesis of pyridazines. Since that moment, tetrazine 
chemistry has gained much of attention and it was mostly exploited in organic 
synthesis,4 material5 and coordination chemistry.6 However, a breakthrough was 
achieved in 2008, when Fox reported the first application of tetrazine chemistry for 
protein modification.7 Over the past decade, tetrazines have become one of the 
most promising and powerful bioorthogonal tools used in a variety of biological 
applications. Owing to their high chemical selectivities, rapid reactivities and 
biocompatibility, tetrazines have been exploited in a number of pre-targeting 
applications,8 mainly for nuclear medicine,9 imaging and drug delivery.10 
 
 








1.2 Inverse-electron-demand Diels–Alder reactions  
 
 
The Diels–Alder reactions, discovered by Otto Diels and Kurt Alder in 1928,11 are an 
example of a pericyclic reaction. The [4π+2π] cycloaddition involves the interaction 
between four π-electrons of a conjugated diene with two π-electrons of an 
unsaturated compound, the so-called the dienophile, to form a partially unsaturated 
six-membered ring. Normally Diels–Alder (DA) reactions occur between electron-
poor dienophiles and electron-rich dienes and, according to the Frontier Molecular 
Orbital Theory (FMO theory) proposed by Hofmann and Woodward,12 the overall 
reactivity is determined by the interaction between the Highest Occupied Molecular 
Orbital of the diene (HOMOdiene) and the Lowest Unoccupied Molecular Orbital of the 
dienophile (LUMOdienophile) (Figure 1.2). In contrast, IEDDA reactions are 
transformations in which dienes are electron-poor whereas the dienophiles are 
electron-rich moieties hence the cycloaddition reaction occurs between the 
HOMOdienophile–LUMOdiene (Figure 1.2). The reaction rate of Diels–Alder 
cycloadditions strongly depends on the difference in energy between the HOMO and 
the LUMO (ΔE) of the two reactants: the smaller the gap, the faster the reaction. 
The rate can easily be tuned by modifying the substituents on either the diene or the 
dienophile, and specifically in IEDDA, the reaction is accelerated when electron-
donating groups (EDG) are installed on the dienophile, while electron-withdrawing 






Figure 1.2. Comparison between the energies of the molecular orbitals involved in normal 
and inverse [4+2] Diels–Alder reactions. 
 
In 1959, Carboni and Lindsey discovered that, due to their electron-poor nature, 
tetrazines can act as dienes in IEDDA reaction with various dienophiles (i.e. alkenes 
and alkynes).3 The reaction proceeded via [4+2] cycloaddition between the tetrazine 
and the unsaturated compound, resulting in the formation of a strained bicyclic 
intermediate which immediately undergoes a retro-Diels–Alder (rDA) step resulting 
in the loss of nitrogen and formation of a 4,5-dihydropyridazine. Upon 
tautomerisation, the 1,4-dihydropyridazine is formed which can then be 





Figure 1.3. Mechanism of the IEDDA reaction between a tetrazine and an alkene, resulting 
in the formation of the pyridazine. 
 
Consistently with the FMO theory, the reactivity of tetrazines in the IEDDA can be 
modulated by changing substituents on the DA partners. Boger13-16 and Sauer17-19 
extensively investigated the electronic and steric effects of the substituents on both 
the diene and the dienophile by comparing the reactivity of various 3,6-disubstituted 
tetrazines. More electron-deficient tetrazines, bearing EWG groups (e.g. carboxylate, 
pyrimidyl, pyridinyl groups), showed faster reaction rates than electron-rich 







Figure 1.4.  Electronic effect of the substituents on tetrazine reactivity in IEDDA chemistry 
(adapted from Knall et. al. Chem. Soc. Rev. 2013, 42, 5131 and Bernardes et. al. Chem. Soc. 
Rev., 2017, 46, 4895).   
 
Sauer evaluated the rate enhancement induced by structural and electronic 
variations on the dienophile determining the second-order rate constant of the 
reaction between 3,6-dicarboxylate-1,2,4,5-tetrazine and various cyclic and acyclic 
dienophiles (e.g. cyclic alkenes, styrene, vinyl ether, enamine, acetylene) (Figure 
1.5).17, 23 Since donor substituents raise the energy of the HOMOdienophile, an increase 
in reactivity was observed when EDG (e.g. dialkylamino, enamines, alkoxy moieties) 
were present on the dienophile. Additionally, a remarkable acceleration was also 
noticed when increasing the degree of ring strain. On this basis, Sauer identified 
some key trends that govern the rate of this transformation; olefinic dienophiles are 
more reactive than acetylenic ones, electron-donating substituents tremendously 
increase the reaction rates (with dialkylamino, enamines, ynamines showing the 
best results) although bulkier substituents (e.g. alkoxy and thioalkyl groups) impede 
the enhancement in reactivity due to the steric effects. Strained cyclic dienophiles 
showed an outstanding increase in reactivity, with the trans-cyclooctene displaying a 
k2 ~ 10






Figure 1.5. Evaluation of electronic and steric effects of the substituents of the dienophiles in 
the IEDDA with 3,6-dicarboxylate-1,2,4,5-tetrazine (adapted from Sauer et. al. Eur. J. Org. 
Chem. 1998, 12, 2885 and Bernardes et. al. Chem. Soc. Rev., 2017, 46, 4895). 
 
As for normal Diels–Alder cycloadditions, solvent plays a crucial role in the 
acceleration of IEDDA reactions. Protic solvents, in particularly water, can enhance 
the hydrophobic–hydrophobic interactions between the tetrazine and the dienophile 
during the [4+2] cycloaddition step, leading to a great increase in the rate of the 
reaction.17, 24-26 Moreover, protic solvents promote formation of hydrogen bonds with 
tetrazines, resulting in a lowering of the LUMO thus boosting the rate of the reaction. 
Acidic pH can also help to accelerate the reaction, especially when the tetrazine is 
modified with a pyridine group.21 
Since unmodified and linear alkenes show poor reactivity towards tetrazines, in the 
past decade, great interest has focussed on the synthesis and evaluation of strained 
dienophiles as tetrazine partners in IEDDA reactions, with trans-cyclooctenes, 
norbornenes, cyclopropenes being the most used. However, their large size and 
poor stability can sometimes prevent their use, especially in chemical biology 
applications, and therefore there has been continuous research in expanding the 
scope of dienophiles.21 Smaller and more accessible dienophiles, such as 




alternatives to highly strained dienophiles that are more accessible and stable 
although with slightly slower reaction rates.10, 21, 34 Since the substituents on the 
tetrazine ring greatly influence the reaction rate and stability, significant effort has 
been also made in tuning the reaction rates by synthesising new tetrazines.   
 
1.3 Synthesis of s-tetrazines 
 
Tetrazines are usually obtained from the oxidation of their dihydrotetrazine 
precursors via a two-step procedure. The first synthesis goes back to 1893, when 
Pinner constructed the s-tetrazine ring by reacting an imidoester with an excess of 
hydrazine.2 Several studies have been reported to elucidate the key factors 
governing this transformation with different mechanistic pathway proposed. One of 
the most credited suggests that the reaction starts with nucleophilic attack of the 
hydrazine to the imidoester to form the amidrazone which subsequently reacts with 
another equivalent of the imidoester to give the 1,2- or 1,4-dihydrotetrazine, which is  
subsequently oxidised to the tetrazine (Figure 1.6).35  
 
Figure 1.6. Proposed mechanism for the synthesis of s-tetrazines starting from the 




A few years later, Pinner reported another route to access s-tetrazines via a two-
step procedure starting with two aromatic nitriles in the presence of hydrazine.36 A 
condensation reaction between two molecules of benzonitrile and hydrazine led to 
the formation of the dihydrotetrazine which can be oxidised to the aromatic tetrazine 
(Figure 1.7). To date, this route represents, by far, the most used procedure to 
access symmetric s-tetrazines, however, with some limitations. This protocol is in 
fact ideal for aromatic nitrile compounds, but often not applicable to unactivated 
nitriles (i.e. aliphatic and alkyl nitriles). In addition, this transformation is less ideal for 
the synthesis of asymmetric tetrazines. In such cases, the use of a large excess of 
one nitrile is necessary and often still generates mixture of products in poor yields 
which are difficult to purify.  
 
 
Figure 1.7. Condensation of two aromatic nitriles in the presence of hydrazine. 
 
Tolba reported a modified-Pinner synthesis whereby elemental sulphur is used as a 
catalyst to improve the yields of both symmetric and asymmetric tetrazines (60–
70%).37  In a proposed mechanism, sulphur is suggested to react with hydrazine to 
form the hydrazide NH2NHSH which subsequently reacts with a nitrile to give the 
corresponding amidrazone. Upon condensation with a second nitrile, a reactive 
intermediate is formed that eliminates hydrogen sulphide (SH2) and is converted to 
the dihydrotetrazine scaffold after electrocyclic rearrangement. A subsequent 
oxidation gives the desired tetrazine in moderate yield (Figure 1.8). Li exploited this 
strategy to synthesise 18 novel 3,6-di-substituted tetrazines, by reacting various 
aromatic nitriles with hydrazine monohydrate in ethanol at 78 °C for 12 hours using 




synthesis of tetrazine starting from aromatic nitriles (e.g. benzonitrile derivatives), 
these conditions are still not efficient for the synthesis of alkyl tetrazines, for instance 
3,6-dimethyl-1,2,4,5-tetrazine, are formed in poor yields (20%) and the method 
completely failed for the synthesis of tetrazines starting from sterically hindered 
nitriles (e.g. o-methylbenzonitrile). 
 
 
Figure 1.8. Proposed mechanism of the sulphur-catalysed Pinner reaction for the synthesis 
of 3,6-disubstituted symmetric and asymmetric tetrazines and substrate scope (adapted from 
Audebert  et. al. Chem. Soc. Rev. 2010, 110, 3299 and Li et. al. RSC Adv. 2015, 5, 12277). 
 
Hu demonstrated, based on Carboni’s work39, that gem-difluoroalkenes can be 
exploited for the synthesis of 3,6-dibenzyl-12,4,5-tetrazine derivative in high yields 
(76–87%) and on gram scale (Figure 1.9).40 The reaction between a gem-




species which was observed by 1H and 19F NMR spectroscopy.  The self-
condensation of fluorohydrazones followed by oxidation in air resulted in the 
formation of di-substituted tetrazines in much better yields (~ 40% higher) than 
traditional methodologies. 
 
Figure 1.9. Synthesis of di-substituted tetrazines starting from gem-difluoroalkenes followed 
by oxidation in ambient air (adapted from Hu et. al. Green Chem  2017, 19, 1299). 
 
Alkyl-substituted tetrazines are more challenging to synthesise due to the reduced 
electrophilic character of the nitrile group which decreases its reactivity towards 
hydrazine, and due to the formation of side products during the cyclization step (e.g. 
formation of 1,2,4-triazoles), occurring especially for bulky alkenyl nitriles.41, 42  
In order to avoid the formation of these by-products, Werber43 and Erickson41 
proposed an alternative strategy for the synthesis of asymmetric s-tetrazines starting 
from the S-methylthiocarbohydrazide (Figure 1.10). Its reaction with various 
carboxylic acid derivatives led to the formation of 6-alkyl-3-(methylthio)-1,2,4,5-







Figure 1.10. Synthesis of asymmetric s-tetrazines via cyclization of S-
methylthiocarbohydrazide with dithiobenzoate esters, orthoesters and amide acetal 
derivatives. The 6-alkyl-3-(methylthio)-1,2,4,5-tetrazine formed can be further functionalised 
through SNAr chemistry with several N- and O-nucleophiles. 
 
 
1.4 Transition metal-catalysed synthesis of tetrazines 
 
The field of organic chemistry has been entirely revolutionised thanks to the advent 
of transition metal catalysis.44, 45 Novel pathways with reduced activation energy 
have been reported which have allowed development of synthetic protocols for the 
synthesis of structurally challenging molecules in high yields and with high functional 
group tolerance.46 In this context, a natural step was the implementation of a 
transition metal-catalysed protocol for the synthesis of tetrazines. Metal species are 
known to be coordinated by nitrile groups, making them more susceptible to 
nucleophilic attack.47 Recently, Devaraj reported a metal-catalysed approach to 
promote the synthesis of s-tetrazines. Screening 24 Lewis acids for the synthesis of 
the symmetric 3,6-dibenzyl-1,2,4,5-tetrazine using anhydrous hydrazine at 60 °C for 
24 hours (Table 1.1), it was found that the addition of 5 mol% of a Lewis acid, 
remarkably improved the yields compared to the uncatalysed reaction (Entry 1), with 
the best results obtained using nickel and zinc triflates.48 Those catalysts were then 











 Yield Entry Catalyst
[a]
 Yield Entry Catalyst
[a]
 Yield 
1            − 0% 9 Sc(OTf)3 26% 17 Cu(OTf) 57% 
2 Ni(acac)2 10% 10 Yt(OTf)3 31% 18 Cu(OAc)2 59% 
3 Cu(OTf)2 11% 11 Zn(OAc)2 38% 19 MgCl2 63% 
4 ZnCl2 11% 12 CuBr 42% 20 ZnI2 68% 
5 CuCl 12% 13 ZnBr2 46% 21 Zn(OTf)2 70% 
6 CoCl2 · 6 H2O 13% 14 CuI 50% 22 NiCl2 73% 
7 MgBr2 15% 15 CuOAc 53% 23 NiI2 93% 
8 CuBr2 23% 16 MnBr2 55% 24 Ni(OTf)2 95% 
[a] 
Catalyst loading: 5 mol%. 
Both zinc and nickel triflates allowed the synthesis of several symmetric and 
asymmetric tetrazines in higher yields compared to previously reported sulphur-
catalysed methodology and with better substrate scope. This time it was possible to 
promote the activation of the less reactive aliphatic nitriles, enabling the synthesis of 
mono- and di-substituted alkyl tetrazines, difficult to prepare via the Pinner reaction. 
In addition, it was observed that zinc triflate was more effective for less active nitriles 
(i.e. aliphatic and sterically hindered nitriles) providing the tetrazines in modest 
yields. In contrast, nickel triflate was more efficient for the synthesis of numerous 
mono-substituted tetrazines starting from more active nitriles (aromatic nitriles), 
providing the corresponding tetrazines in much better yields also when the reaction 





Figure 1.11. Evaluation of Zn(OTf)2 and Ni(OTf)2 for the synthesis of symmetric and 
asymmetric tetrazines (adapted from Devaraj et. al. Angew. Chem. 2012, 51, 5222). 
 
This strategy was also demonstrated to be effective for the synthesis of 6-hydrogen-
terminated tetrazines starting from aromatic nitriles and formamidine salts (Figure 






Figure 1.12. Synthesis of mono-substituted 6-H-1,2,4,5-tetrazines via the zinc and nickel-
catalysed Pinner reaction starting from aromatic nitriles and formamidine salts (adapted from 
Devaraj et. al. Angew. Chem. 2012, 51, 5222). 
 
This metal-catalysed approach has impressively contributed to broadening the 
scope of challenging s-tetrazines allowing access from very unreactive precursors 
and with significantly increased yields. Although several tetrazines have been 
synthesised using this methodology, the substrate scope is still limited by the use of 
hazardous anhydrous hydrazine and high temperatures, and functional groups 
sensitive to nucleophilic addition or reduction (e.g. carbonyl and alkyl halides) are 
not suitable for this procedure.49 
Recently, several cross-coupling reactions (e.g. Sonogashira, Negishi, Stille, Suzuki 
and Heck) have been exploited for the direct incorporation of functionalities on the 
tetrazine core. Kotschy was the first to report the synthesis of asymmetric tetrazines 
via Sonogashira and Negishi cross-coupling reactions using 3-substituted-6-
chlorotetrazines, readily prepared by displacement reaction of the chlorine group 
from commercially available 3,6-dichloro-1,2,4,5-tetrazine (Figure 1.13).50 During 
screening a strong correlation between EDG substituents and tetrazine reactivity 
towards cross-coupling reaction emerged. In fact, only deactivated tetrazine, bearing 
one EDG substituent (e.g. alkoxy, alkylamino and alkylthio groups), were reactive 
under Sonogashira and Negishi conditions, while more electron-deficient 
chlorotetrazines were unstable, leading to decomposition. Diethylamine, morpholine 
and pyrrolidine-substituted chlorotetrazines were synthesised and reacted with 




giving the coupling products in moderate yield (23–65%). In contrast their reaction 
with hexynylzinc chloride in the presence of 7 mol% Pd(Ph3)2Cl2 gave the Negishi 
coupling products in lower (32–34%) yields.  
 
Figure 1.13. Cross-coupling reactions applied to the synthesis of asymmetric tetrazines by 
direct modification of the tetrazine core. 
 
Later, Wombacher successfully reported tetrazine–BODIPY and tetrazine–
fluorescein probes linked through a fully conjugated π-systems and showing 
minimal background fluorescence, synthesised by Sonogashira coupling using iodo- 
or acetylene-substituted 6-methyltetrazines as a precursor (Figure 1.14). 51  
 
 





Guillaume, inspired by Kotschy’s work, demonstrated that tetrazine synthesis via 
Suzuki-like and Stille-like cross-coupling reactions could be achieved using 3-
methylthiotetrazine derivatives as a building block (Figure 1.15).52 
Methylthiotetrazines showed no degradation under the reaction conditions and good 
reactivity towards electron-rich and electron-poor arylboronic acids and 
organostannates in the presence of 5 mol% of Pd(Ph3)4 and copper(I) thiophene-2-
carboxylate resulting in the formation of the coupling products in good yields (28–
67% and 30–52% for Suzuki and Stille couplings, respectively). A screening of 
reaction conditions showed that microwave irradiation (200 °C) was beneficial to the 
reaction times (48 to 2 hours), and to the reaction yields (with 5–10% increases in 
yield).  
 
Figure 1.15. Synthesis of asymmetric tetrazines via Suzuki-like and Stille-like cross-coupling 
reactions. 
 
Suzuki and Stille cross-coupling reactions have recently been optimised by Kele53 
and Wombacher54 and applied to the synthesis of fluorescein, Oregon green and 
phenoxazine-based tetrazine fluorescent probes, although in moderate yields (10–





Figure 1.16. Fluorescein and phenoxazine probes reported by Wombacher and Kele 
synthesised through Suzuki and Stille coupling reactions, respectively. 
 
Reaction conditions for Suzuki coupling have been optimised by Lindsley55 using a 
third generation palladacycle catalyst (BrettPhos Pd G3) and substrate scope was 
extended to amino-functionalised tetrazines, beyond morpholino-substituted 
systems (Figure 1.17). 
 
Figure 1.17. Reaction scheme and selected examples from the substrate scope for the 






Devaraj and co-workers synthesised 24 π-conjugated (E)-3-substituted 6-alkenyl-
1,2,4,5-tetrazines via an in situ elimination–Heck cascade reaction in which a novel 
tetrazine mesylate was reacted with an aryl halide in the presence of 3 mol% of 
[Pd2(dba)3] and 12 mol% of the ferrocene derivative as a ligand (Figure 1.18). The 
reaction assisted by microwave irradiation provided the coupling products in nearly 
quantitative yields.56 
 
Figure 1.18. Reaction scheme and selected examples of the Heck cross-coupling reaction 




1.5 Other synthetic methodologies  
 
Wang reported an alternative procedure, based on the previous work by Stolle,57 
where the synthesis of s-tetrazines bearing aliphatic or EWG groups was achieved 
from inexpensive and commercially available acyl chlorides precursors.58 Their 




dichloromethylene hydrazides that can be transformed to tetrazines upon treatment 
with hydrazine followed by oxidation (Figure 1.19). Using this methodology, several 
electron-deficient tetrazines were synthesised in moderate yield (~ 50%). 
 
Figure 1.19. Stolle approach for the synthesis of s-tetrazines starting from acyl chlorides.  
 
Later on, the same group reported an improvement of this strategy using microwave 
irradiation to assist the formation of 1,2,4,5-tetrazine ring.59 The condensation 
between hydrazine and the 1,2-dichloromethylene hydrazides occurred faster upon 
microwave irradiation, reducing the reaction time from 5–24 hours to 30 minutes at  
and with 10–20% increases in yield. 
Alternatively, several asymmetric and symmetric tetrazines have been synthesised 
through aromatic nucleophilic substitution (SNAr) of suitable tetrazine precursors, the 
electron-deficient nature of tetrazines makes them perfect substrates for the 
nucleophilic attack by alcohols, thiols and amines when suitable leaving groups are 
in positions 3- or 6- of the tetrazine without needing Pd catalysis. Versatile scaffolds 
for this reaction are the 3,6-bis(thiomethyl)-1,2,4,5-tetrazine, the 3,6-dichloro-
1,2,4,5-tetrazine and the 3,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine 





Figure 1.20. A) Tetrazine precursors for aromatic nucleophilic substitution (SNAr) chemistry. 
B) Proposed mechanism for asymmetric functionalization of s-tetrazines via SNAr reaction, in 
which alkylsulfanyl and halogen groups are readily displaced by neutral or anionic 
nucleophiles (adapted from Audebert et. al. Eur. J. Org. Chem. 2009, 6121). 
 
Audebert exploited this strategy for the synthesis of several mono-substituted and 
di-substituted tetrazines via reacting 3,6-dichloro-1,2,4,5-tetrazine with various 
nucleophiles (e.g. alcoholates, alcohols60 and lithium alkynes62), however strong 
nucleophiles such as alcoholates and lithium alkynes led to degradation products 





Figure 1.21. Examples of tetrazines reported by Audebert synthesised via SNAr chemistry 




Despite this methodology has enabled the synthesis of asymmetric di-substituted 
tetrazines, the SNAr chemistry is limited to substitution reactions with mostly aliphatic 
alcohols and amines (in the presence of a base), which make the tetrazine core less 
reactive towards IEDDA due to their electron-donating character. Only a limited 
number of carbon nucleophiles, such as cyanides, malonic acid derivatives have 
been successfully used to directly functionalise the tetrazine, whereas stronger C- 
nucleophiles (such as Grignard, organolithium and organozinc compounds) cause 
degradation of the tetrazine core.35 Therefore, there is continuing demand to find 
more efficient procedures for their synthesis.  
Recently, Wu, inspired by the reversible interactions observed between nitriles and 
thiols in biological environments, investigated various thiol-containing 
organocatalysts for the synthesis of symmetric and asymmetric 1,2,4,5-tetrazines.63 
The authors hypothesized that thiols could reversibly react with aliphatic and 
aromatic nitriles, forming thioimidate esters in situ. This reactive intermediate can be 
subsequently attacked by hydrazine, leading to the formation of the amidrazone and 
regenerating the thiol organocatalyst. The formation of the tetrazine ring is then 
achieved upon reaction between the amidrazone and another equivalent of 






Figure 1.22. Proposed mechanism for the synthesis of 1,2,4,5-tetrazine with thiol-containing 
organocatalysts (adapted from Wu et. al. Angew. Chem. 2019, 58, 1106). 
 
This approach allowed a high yielding (35–75%) synthesis of 14 tetrazines with the 
best results achieved using 3-mercaptopropionic acid or glutathione as a catalyst 
with hydrazine monohydrate and ethanol as co-solvents (Figure 1.23). These mild 
reaction conditions enabled the synthesis of tetrazines bearing various functional 
groups, e.g. carboxylic acid, amino, alkyl and alkoxy functionalities, difficult to 
synthesise with previously reported strategies.  
 
Figure 1.23. Synthesis of asymmetric tetrazines via 3-mercaptopropionic acid-assisted 
procedure and selected examples from the substrate scope (adapted from Wu et. al. Angew. 




The methylphosphonate tetrazine derivative was used as a building block for 
Horner–Wadsworth–Emmons reaction with various aldehydes which provided (E)-3-
substituted 6-alkenyl-1,2,4,5-tetrazines in excellent yield (87–94%), including a 
fluorogenic tetrazine–BODIPY in higher yield compared to the previous Heck cross-
coupling chemistry (Figure 1.24).56 Although the substrate scope still needs to be 




Figure 1.24. Reaction scheme and selected examples from the substrate scope for the 
synthesis of (E)-3-substituted 6-alkenyl-1,2,4,5-tetrazines via Horner–Wadsworth–
Emmons chemistry (adapted from Wu et. al. Angew. Chem. 2019, 58, 1106). 
 
Despite the lack of a general procedure for the synthesis of 1,2,4,5-tetrazines, many 
methodologies have greatly contributed to make the 1,2,4,5-tetrazine scaffold 
accessible. However, the synthesis of some tetrazine scaffolds remains very 
challenging or suffers from very complex and tedious purifications and therefore, 
improved synthetic routes are still desirable, as are easier methods of purification. 
Notably, tetrazines that are stable to both physiological pH and serum are urgently 




2. Prodrug–Prodrug activation 
 
This work was done with K. Neumann and parts of this chapter are published in: K. 
Neumann,† A. Gambardella,† A. Lilienkampf, M. Bradley Chemical Science, 2018, 9, 
7198-7203. 
 
2.1 Drug activation strategies 
 
The prodrug approach represents one of the most commonly used strategies to 
improve drug delivery distribution and involves the use of a temporarily protected 
drug, the so-called prodrug, and is often used to reduce side effects of the 
corresponding active drug. Traditionally, prodrug activation strategies have relied on 
activation induced by an internal stimulus, such as pH or enzymes as triggers.64 For 
instance, aldoxorubicin is a prodrug currently in clinical trials for the treatment of 
sarcoma in which the anticancer drug doxorubicin has been decorated with an acid-
labile protecting group (a hydrazone bond) that will be activated by the more acidic 
pH found in cancer tissues (pH ~ 5). Other prodrugs include esters or phosphate 
groups, such as capecitabine, deflazacort, isavuconazonium sulfate and fostemsavir 
tromethamine, that are cleaved by enzymes that are over-expressed in cancer (e.g. 
esterases, proteases and phosphatases, Figure 2.1).65, 66 As an example, 
capecitabine is an FDA-approved prodrug utilised for treatment of several types of 
cancer, such as breast, stomach, and colorectal cancers. The activation of 
capecitabine occurs in three enzymatic steps and starts in the liver with its 
hydrolysis induced by carboxylesterases to form 5’-deoxy-5-fluorocytidine (5’-
DFCR). The 5’-DFCR is then converted in the liver or in the tumour to 5’-deoxy-5-
fluorouridine (5’-DFUR) by cytidine deaminase. Finally, the thymidine 
phosphorylase, over-expressed in tumours, converts 5’-DFUR to the active 5-
fluorouracil (5-FU) (Figure 2.2).67  
The selectivity of these methods of activation depends on differences between the 
microenvironment found in healthy and cancer tissues. Despite their wide use in 
clinic, these strategies often suffer poor selectivity and lack temporal and 
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quantitative control, since only a few enzymes are specifically located in cancer 
cells, resulting in the premature and non-specific activation of the prodrug.68  
 
 
Figure 2.1. Structures of prodrugs used in clinic and activated by esterases and 
phosphatases over-expressed in tumour tissues, or aberrant physiological parameters such 
as pH. 
 
Methodologies that offer a more controllable and selective activation are desirable 
and, recently, bioorthogonal reactions – a class of chemoselective transformations 







Figure 2.2. Metabolic pathway of capecitabine activation to release the anticancer drug 5-
fluorouracil (5-FU).  
 
Robillard reported the use of the bioorthogonal Staudinger reaction for prodrug 
activation where an azido-functionalised prodrug 1 was de-masked, upon reaction 
with a tris(3-sulfophenyl)phosphine 2, releasing the anticancer drug doxorubicin 
(DOX) (Figure 2.3).72 The effective release of the anticancer drug was shown in 
A431 human skin carcinoma cells by administration of the prodrug 1 (10 µM) and 
multiple doses of the phosphine 2 (5 × 60 µM), resulting in reduction of cell 
proliferation. Despite the potential of this reaction in vitro, the poor reactivity (k2 
~10−3 M−1 s−1) and poor stability of the phosphine reagents would limit the use of this 
approach for in vivo applications.  
In order to address these issues, Gamble reported an improvement using a strain- 
promoted 1,3-dipolar cycloaddition reaction,73 showing the effective release of the 
active DOX drug (51% in 4 hours) using the same azido-functionalised prodrug 1 
(100 µM) used but incubated with trans-cyclooctenol 3 (TCO, 500 µM) (Figure 2.4). 








Figure 2.3. Activation of protected doxorubicin 1 via a Staudinger reaction triggered by 
tris(3-sulfophenyl)phosphine 2 and followed by spontaneous 1,6-elimination and 
decarboxylation of the p-aminobenzyloxycarbonyl linker. 
 
To circumvent these limitations, bioorthogonal reactions that exhibit higher reactivity 
and stability of the reactants are highly desirable for in vivo applications. In 2008, a 
new approach emerged with the use of the inverse-electron-demand Diels–Alder 
reaction (IEDDA) between strained alkenes, such as the trans-cyclooctenes, and an 
electron-deficient tetrazine.7 The reaction showed high chemoselectivity and 
exceptionally fast reaction rates (k2 = 1–10
4 M−1 s−1) in aqueous solution, 
establishing itself as a promising bioorthogonal reaction. 
The biocompability and suitability of IEDDA for in vivo applications was confirmed by 
Robillard74, 75 and Weissleder76, who reported its use in mice for tumour 
radioimmunoimaging, although the tetrazines reported were actually later observed 






Figure 2.4. The strain-promoted 1,3-dipolar cycloaddition between the protected doxorubicin 
1 and TCO 3. After the cycloaddition step, the adduct 4 spontaneously rearranges into the 
intermediate 5 releasing nitrogen. The intermediate 5 undergoes hydrolysis and 1,6-
elimination to release the free doxorubicin. 
 
In 2013, Robillard showed the rapid release of DOX triggered by the reaction with 
tetrazines. Knowing that the cycloaddition between the trans-cyclooctenol 6 (TCO) 
and tetrazine 7 leads to the formation of the 4,5-dihydropyridazine 8 that readily 
tautomerises to the 1,4-dihydropyridazine 9 (Figure 2.5), Robillard designed the 
prodrug 10 coupling DOX to the allylic position of the TCO via a carbamate. The 
cycloaddition with tetrazine 11 followed by tautomerisation of the adduct 12 and 
subsequent rearrangement resulted in decaging of DOX (Figure 2.5).77 Interestingly, 
they observed significant reduction in reactivity of the equatorial-substituted TCO, 
156-times slower than the corresponding axially-substituted TCO, presumably due 
to unfavourable steric interactions between the tetrazine and the carbamate 
moieties.  
They evaluated this reaction on A431 tumour cells, with co-treatment with tetrazine 
11 (10 M) and the prodrug 10 (1 M) and an increase in cytotoxicity (EC50: 0.05 





Figure 2.5. A) Mechanism for the IEDDA between the trans-cyclooctenol 6 and a generic 
tetrazine 7 followed by the retro-Diels–Alder to form the 4,5-dihydropyridazine 8. In aqueous 
conditions 8 spontaneously tautomerises to the 1,4-dihydropyridazine isomers 9. B) Example 
of the IEDDA ligation used for drug delivery. The potent anticancer drug (DOX) has its amino 
group protected through a carbamate linker to the allylic position of TCO and is efficiently 
released upon tetrazine-triggered IEDDA reaction and subsequent decarboxylation (adapted 
from Robillard et. al. Angew. Chem. 2013, 52, 14112). 
 
The TCO derivatives have been demonstrated to be excellent partners for IEDDA-
triggered “click-to-release” strategies;78-80 however, their synthesis can be laborious 
and natural isomerisation to the less strained cis analogue nullifies their reactivity 
therefore limiting their use.  
Recently, vinyl ethers have been demonstrated as dienophiles in IEDDA for the 
decaging of alcohol-containing cargos in living cells based on the initial work of 
Boger.14, 22, 33  Bernardes reported the activation of a vinyl ether-caged anticancer 
drug 16 upon IEDDA in cancer cells (Figure 2.6),81 where the halogen-bearing 




protected with a vinyl ether moiety, envisioning that the cascade reaction between 
the prodrug 18 and the tetrazine 19 was followed by a spontaneous Winstein 
spirocyclization resulting in the formation of the duocarmycin 16.82-84 The effective 
release of 16 was observed in A549 and HepG2 cells upon treatment of with the 
prodrug 18 (10 µM) with tetrazine 19 (20 µM) after 72 hours. The protected 
duocarmycin 18 showed no degradation after 8 hours in DMF/H2O (9:1), however no 
stability studies were conducted in cell culture media. 
 
Figure 2.6. Activation of “dual-masked” anticancer drug duocarmycin 18 triggered by a 
cascade reaction between the tetrazine and the vinyl ether moiety followed by spontaneous 
Winstein spirocyclization to release the cytotoxic drug 16 within 72 hours in A549 cells. 
 
Our group exploited the vinyl ether for the efficient release of doxorubicin, which was 
covalently attached to polymeric nanoparticles (NP) through a self-immolative 
linker.31 The incubation of  the DOX-NP’s 20 (1 µM) with tetrazine 21 (35 µM) for 48 
hours with PC3 and HEK293T cells triggered the IEDDA reaction followed by the 
spontaneous 1,6-elimination of the adduct 22 leading to nanoparticle destruction 
and in situ generation of the doxorubicin, resulting in an increase in cell death of 





Figure 2.7. Decaging of DOX from a tetrazine-responsive self-immolative linker. The IEDDA 
reaction between the 3,6-di-2-pyridyl-1,2,4,5-tetrazine 21 and the vinyl ether is followed by a 
spontaneous 1,6-elimination reaction and decarboxylation of 22 and leads to the release of 















2.2 Project aims 
 
 
The clinical treatment of cancer often uses two or more drugs, with tumour tissues 
known to have an increased uptake of drugs due to their abnormal growth. In 
traditional prodrug activation strategies, the premature release of a cargo still 
represents a major concern and patients suffer in general from off-target toxicities 
because of the poor selectivity of drugs. The use of chemoselective transformations 
to activate a prodrug could potentially enable a more selective spatio-temporal 
control of the drug release and therefore could help to deliver the payload to the 
desired target site, thus reducing off-target effects. Bioorthogonal chemistry has 
recently emerged as a promising approach for prodrug activation, however, it is still 
in its early stages and needs further optimisation before being applied in clinic. 
As discussed above, among the plethora of bioorthogonal reactions reported, 
IEDDA between a tetrazine and a suitable dienophile is one of the most remarkable, 
yet there are some challenges that remain to be addressed. In particular, the 
TCO/tetrazine pair exhibits fast reaction rates (k2 = 1–10
4 M−1 s−1) but the complex 
synthesis of TCO–drug derivatives (up to 8 synthetic steps)80 together with their low 
stability in cellular environment (isomerisation to the inactive cis-cyclooctene (CCO)) 
is a major limitation. The vinyl ether/tetrazine pair has lower reactivity (k2 ~ 10
−4 M−1 
s−1), but are synthetically more accessible (usually just one synthetic step)31, 81, 85 
and show higher hydrolytic stability.10 In all of these strategies, tetrazines are used 
as bioorthogonal trigger and alongside the activation of the desired drugs, there is 
still the formation of by-products, which makes the overall strategy inefficient and not 
fully bioorthogonal. 
The aim of my work was focussed on the design and synthesis of a 
dienophile/tetrazine pair that could lead to simultaneous and prolonged activation of 
two prodrugs (Figure 2.8). Specifically, it was explored if tetrazines could act not 






Figure 2.8. Proposed mechanism for the cascade reaction between a “tetrazine-masked” 
and a “vinyl ether-protected” prodrugs to give two drugs. 
 
2.3 Design of the prodrugs 
 
MicroRNAs (miRNA) are a class of gene regulators formed by short noncoding 
single-stranded RNA (~ 22 nucleotides), which can act as tumour suppressors and 
their dysregulation is associated with several diseases, especially cancer.86, 87 
miRNA-21 is an anti-apoptotic factor highly overexpressed in many cancers (e.g. 
brain, breast, lung cancers and glioblastomas).88 Recently, Deiters reported an 
assay for the identification of small molecules able to modulate miRNA activity, and 
specifically, they reported pyridazine-based 24 as a miRNA-21 inhibitor (Figure 
2.9).89, 90  
 
Figure 2.9. Structure of the 3-(methylthio)-6-(3-nitrophenyl)-pyridazine 24, a miRNA-21 
inhibitor. 
 
Since pyridazines are generated from tetrazines upon an IEDDA reaction with 
dienophiles, the great potential of tetrazines to act not only as a masking moiety for 
bioactive pyridazines, but also as a prodrug in their own right was explored. Thus 
the pyridazine-based miRNA-21 inhibitor 24 was selected as a drug for this 
prodrug–prodrug activation strategy.  
Camptothecin (CPT) is a natural occurring alkaloid (Figure 2.10), first isolated in the 




In the 1970s, CPT was approved by the US Food and Drugs Administration (FDA) 
after phase I and phase II clinical studies established its remarkable anti-tumour 
activity; however, its low solubility and stability, and its side effects stopped its 
clinical application.92 In the 1980s, it was found that CPT plays a pivotal role in cell 
replication, binding to the otherwise reversible complex between DNA and 
Topoisomerase I (Topo I), forming a stabilised ternary complex (DNA–CPT–Topo I), 
which results in arrest of the replication fork and induces cell death (Figure 2.11). 
Structure–activity studies showed that the potent anti-cancer activity is strongly 
linked to the lactone ring and to the C-20 hydroxy group on CPT (Figure 2.10), 
which form hydrogen bonds with an arginine (Arg364) and an aspartic acid (Asp533) 
on the side chain of the DNA–Topo I complex, promoting complex stability. The CPT 
loses its anti-cancer activity when the configuration of the C20 is (R) and when the 
lactone ring is hydrolysed to its open form.92 
 
Figure 2.10. Structure and binding sites of CPT. The CPT forms multiple hydrogen bonds 







Figure 2.11. A) Mechanism of action of Topo I uncoiling the DNA and facilitating the 
advancement of the replication fork. B) Mechanism of action of CPT. The CPT binds to the 
DNA–Topo I complex preventing the re-ligation of the nicked DNA and the dissociation of the 
DNA–Topo I complex. This causes the arrest of the replication fork and induces DNA 
breakage resulting in cell death. 
 
It was envisaged that effective protection of the hydroxy group with a vinyl ether 
would provide a powerful strategy to block the anti-tumour activity of CPT while 
making it a tetrazine-responsive prodrug. 
Thus, the pyridazine-based miRNA-21 inhibitor 24 and CPT were selected as target 
compounds for the prodrug–prodrug activation strategy, picturing that their dual 
activation could be triggered using the tetrazine 25 and a vinyl ether camptothecin 
derivative 26 as bioorthogonal partners (Figure 2.12). 





Figure 2.12. Drugs 24 and CPT, selected for the dual prodrug activation. The reaction 
between the tetrazine-protected drug 25 and a vinyl ether-masked anti-cancer drug 26 
results in the formation of two corresponding drugs, the pyridazine-base microRNA-21 
inhibitor 24 and the free anti-cancer drug CPT.  
 
 
2.4 Synthesis of the key compounds 
 
The most common synthetic strategies to access asymmetric tetrazines are the well-
established reactions between an imidoester and a hydrazine, with nucleophilic 
aromatic substitution (SNAr) of a symmetric 3,6-bis(methysulfanyl)-1,2,4,5-tetrazine 
obtained via cyclization of S-methylisothiocarbohydrazides.21 Thus, the synthesis of 
the asymmetric tetrazine prodrug 25 was attempted first via a nickel-catalysed 
Pinner reaction of methyl thiocyanate 27 and 3-nitrobenzonitrile 28 (Scheme 2.1); 




Scheme 2.1. Unsuccessful synthesis of tetrazine 25 by a nickel-catalysed Pinner reaction. 
Reaction conditions: 1) Methyl thiocyanate 27 (25 mmol), 3-nitrobenzonitrile 28 (0.5 mmol), 
nickel triflate (0.25 mmol), hydrazine monohydrate (220 µL), 60 °C, 48 h. 2) Amyl nitrate (2.5 





A new route was envisaged for the synthesis of tetrazine 25 using the 
thiocarbohydrazinium salt 30 and the imidoester 31 as precursors (Figure 2.13). 
 
 
Figure 2.13. Retrosynthesis of tetrazine 25. 
 
The thiocarbohydrazinium salt 30 was synthesised by methylation of the 
commercially available thiocarbahydrazide 32 with methyl iodide, according to a 
modified literature procedure (Scheme 2.2),93 which gave the thiocarbohydrazinium 
salt 30 in 77% yield. 
 
Scheme 2.2. Synthesis of the thiocarbohydrazinium salt 30. 
 
The imidoester 31 was accessed via an acid-catalysed addition of EtOH to 3-
nitrobenzonitrile 28, with screening of the reaction conditions shown in Table 2.1.  
Treating 28 with an excess of anhydrous EtOH at room temperature in the presence 
of HCl (4N in dioxane) gave 31 in traces (Entry 1); however, upon increasing the 
amount of the acid (Entry 2 and 3) and increasing the reaction time to 3 days (entry 
4), the imidoester 31 was obtained in 65% yield, with the reaction performed on a 








 time (h) Yield (%) 
1 (0.01 M)/(1.3 M)  18 h Traces 
2 (0.006 M)/(2.6 M) 6 h 18 
3 (0.006 M)/(2.6 M) 18 h 60 
4 (0.006 M)/(2.6 M) 36 h 65 
[a]
 in dioxane. 
 
Tetrazine formation between precursors 30 and 31 was screened in different 
solvents (DMF, H2O, CH2Cl2, EtOH) and bases (pyridine, NaOH, NaHCO3, Na2CO3 
and NEt3). When CH2Cl2 or EtOH were used as solvents no reaction was observed, 
possibly due to the low solubility of the starting materials. Performing the reaction in 
DMF with pyridine, followed by in situ oxidation of the dihydrotetrazine 29 using amyl 
nitrate as a mild oxidant, gave tetrazine 25 in 9% yield, which was the best yield 
obtained (Scheme 2.3). The other bases gave 25 in lower yields (0–5%). 
Remarkably, the reaction with commercially available thiocarbohydrazinium salt 30 
gave the product only in 2% yield, potentially due its poor stability, thus 30 was 
freshly made and used immediately.  
 
Scheme 2.3. Optimised conditions for the synthesis of the tetrazine prodrug 25. 
 
The pyridazine-based miRNA-21 inhibitor 24 was synthesised in two steps starting 
from the commercially available 2,5-dichloropyridazine 33. Nucleophilic aromatic 




thiomethoxidepyridazine 34 in 60% yield. Subsequently, a Suzuki coupling with 3-
nitrophenylboronic gave the pyridazine 24 in 65% yield (Scheme 2.4). 
 
 
Scheme 2.4. Synthetic route to the formation of the miRNA-21 inhibitor 24. 
 
Direct vinylation strategies for CPT were investigated. Those typically involve the 
use of a palladium catalyst (Pd(OAc)2/PPh3) and n-butyl vinyl ether (BVE) as a 
vinylating reagent.94 Unfortunately, this protocol was not successful. After a 
thorough screening of the reaction conditions, the vinylation of the hydroxy group 
was finally achieved using an iridium-promoted trans-vinylation using 10 mol% of 
[Ir(cod)Cl]2, vinyl acetate and Na2CO3 to give protected CPT 26 in poor yield (2%), 
after purification by preparative HPLC (Table 2.2).95 The low yield of the reaction 
was attributed to low conversion (no side products were observed) allowing the 
recovery of unreacted CPT (in 85%). Although the yield was very low, the synthesis 










Table 2.2. Screening reaction conditions for the vinylation of CPT. 
 
Entry solvent [Ir(cod)Cl]2  Base  Vinyl acetate time Yield  
1 1,4-dioxane     1 mol% Na2CO3 
 0.03 M 
0.15 M 4 h 1% 
2 1,4-dioxane 10 mol% Na2CO3  
0.03 M 
0.15 M 3 h 2% 
3 1,4-dioxane 10 mol% Na2CO3  
0.03 M 
0.46 M 3 h 2% 
4 1,4-dioxane 10 mol% Na2CO3 
0.03 M 
0.46 M 24 h - 
5 1,4-dioxane 10 mol% NaHCO3  
0.56 M 
0.15 M 3 h - 
6 toluene 10 mol% Na2CO3  
0.03 M 
0.15 M 3 h 2% 
 
 
2.5 Reactivity and stability of tetrazine 25 
 
The reactivity of the tetrazine prodrug 25 was investigated by determining the 
second-order rate constant (k2) for the reaction with the strained dienophile 5-
norbonen-2-ol 35 (Figure 2.14), a model compound chosen to compare the reactivity 
of 25 with other reported tetrazines.81 The reaction was carried out at 37 °C in 
DMSO/H2O (7:3) using an excess of dienophile 35 (0.025–0.15 M) and monitoring 
the reaction over time measuring the decrease in absorbance of 25 (λ = 520 nm), 
which allowed calculation of k2 (under pseudo first-order conditions). The reaction 
between the tetrazine 25 and 5-norbornen-2-ol 35 proceeded rapidly (k2 = 3.1 ± 0.3 





























Figure 2.14. A) Model reaction between the tetrazine prodrug 25 and the strained dienophile 
5-norbornen-2-ol 35. B) Determination of k2 by plotting kobs against concentration. kobs were 
determined by UV/Vis spectroscopy, monitoring the decay of absorption (at λ = 520 nm) of 
tetrazine 25 (5 mM) using 5-norbornen-2-ol 35 (0.025–0.15 M). 
 
The reactivity of tetrazine 25 was tested with the unstrained dienophile, ethylene 
glycol vinyl ether 36. Since Diels–Alder reactions (normal and inverse electron-
demand) are accelerated with increasing levels of H2O due to enhancement of the 
hydrophobic interactions between the reactants,24, 25 the reaction was performed at 
37 °C with varying ratios of H2O in DMSO (Figure 2.15) The consumption of 
tetrazine 25 was monitored over time and second-order rate constants were 
determined as described above, with a 10-fold increase observed in k2 when H2O 
content was increased from 10% to 50% (Figure 2.15). k2 showed good agreement 
with other dienophiles reported in literature,81 demonstrating the suitability of the 













































Figure 2.15. A) Model reaction between tetrazine prodrug 25 and an unstrained dienophile 
36. B) Determination of k2 by plotting kobs against the concentration of ethylene glycol vinyl 
ether. The kobs were determined by UV/Vis spectroscopy, monitoring the decay of absorption 
(λ = 520 nm) of 25 (5 mM) using 0.05–0.3 M of dienophile 36 with different amounts of H2O 
(10, 30 and 50%). 
 
The stability of tetrazine 25 was compared with the stability of the most commonly 
used tetrazine in biological applications, the commercially available 3,6-di-2-pyridyl-
1,2,4,5-tetrazine 21. Tetrazines 25 and 21 (5 mM) were incubated in DMSO/PBS 
(1:1) and DMSO/H2O (1:1) at 37 °C, and the reaction monitored by the decrease in 
absorbance of tetrazines in DMSO/PBS (1:1) and DMSO/H2O (1:1). This showed 
that tetrazine 25 was 7-fold more stable than tetrazine 21, with a half-life (t1/2) of 2.2 
± 0.5 days and 15.9 ± 4.7 days in DMSO/PBS and DMSO/H2O, respectively. 
Tetrazine 21 showed a half-life (t1/2) of 7.4 ± 0.7 hours and 2.9 ± 0.1 days in 




































Stability in DMSO/H2O (1:1)
 
Figure 2.16. Comparison of the stability of tetrazines 25 and 21 in DMSO/H2O (1:1) (A) and 
DMSO/PBS (1:1) (B). The disappearance of the tetrazine absorbance peak (λ = 540 nm) 
was monitored over time. The half-life (t1/2) was determined by plotting the normalised 
natural logarithm of concentration (ln (ci /c0)) against time. 
 
Tetrazine 25 also exhibited good stability in the presence of biological nucleophiles, 
namely glutathione (GSH). Thus, tetrazine 25 (2 mM) was incubated with GSH (5 
mM) 37 °C and the mixture analysed by HPLC (at λ = 254 nm) (Figure 2.17). A 
comparison between incubation with and without GSH showed 23% and 12% 
decomposition of 25 after 3 days, respectively. Thus tetrazine 25 is much more 













Figure 2.17. HPLC analysis of tetrazine 25 (2 mM) in the presence of GSH (5 mM) in 




2.6 Prodrug–Prodrug activation in cells 
 
A biocompatible dienophile 5’-O-vinyl deoxyuridine 37¥ was used in an initial proof of 
concept study. The cascade reaction between tetrazine 25 and 37 releases miRNA-
21 inhibitor 24 and generates a non-toxic naturally occurring nucleoside 38 (Scheme 
2.5). 
 
Scheme 2.5. Reaction between tetrazine prodrug 25 and a bioorthogonal dienophile 5’-O-
vinyl deoxyuridine 37. 
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The reaction between tetrazine 25 and the vinyl nucleoside 37 was initially 
monitored in vitro, observing the decrease of the tetrazine absorbance (λ = 254 nm) 
by HPLC over time. The reaction was carried out at 37 °C using an excess of 
tetrazine 25 (32 mM) in CH3CN/H2O (1:1). Full conversion was confirmed by the 
HPLC, showing the complete disappearance of the dienophile 37 within 9 days 
(Figure 2.18). 
 
Figure 2.18. HPLC analysis (λ = 254 nm) of the test reaction between tetrazine 25 and the 
dienophile 37, showing the generation of miRNA-21 inhibitor 24 and the free nucleoside 38 
after 9 days.  
 
After testing the in vitro formation of the inhibitor 24, the reaction was tested on 
three cancer cell lines known to overexpress miRNA-21: PC3 prostate, SK-BR3 
breast and U87-MG brain cancer cells.¥  The cytotoxicity of the pyridazine 24, the 
masked nucleoside 37 and tetrazine 25 individually were investigated on each cell 
line (MTT assay, Figure 2.19). Cellular incubation of compound 25 (up to 10 µM) or 
37 (up to 20 µM) did not show significant reduction in cell viability, demonstrating 
that neither compound 25 nor 37 were cytotoxic on their own. Cell viability clearly 
decreased when cells were incubated with both the prodrug 25 (10 µM) and 37 (20 
µM), causing comparable levels of cell death with incubation of the miRNA-21 
inhibitor 24 alone. These results support the generation of 24 in the cell-based 
assays and show the potential of tetrazine as a prodrug scaffold. 
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Figure 2.19. U87-MG, SK-BR-3 and PC3 cancer cells were incubated with tetrazine 25 (10 
µM), 5’-vinyl-O-deoxyuridine 37 (20 µM), miRNA-21 inhibitor 24 (10 µM), and 25 (10 µM) 
together with 37 (20 µM). The cell viability was determined after 72 h of incubation (MTT 




In order to prove that O-vinylated CPT was non-cytotoxic, PC3 cells were incubated 
with CPT or prodrug 26 for 72 h at 37 °C. No significant cytotoxicity was observed 
when the cells were treated with up to 0.5 µM of the vinyl-masked CPT 26 (Figure 
2.20). The protection of the hydroxy group of CPT clearly reduced its anti-cancer 
activity, resulting in an increase in its IC50 from 0.15 µM to 4.64 µM. 
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Figure 2.20. PC3 cancer cells were incubated with prodrug 26 (0.01–100 µM) and CPT 




The reaction between the two prodrugs 25 and 26 was first tested in solution, 
following the disappearance of the tetrazine (λ = 350 nm) by HPLC (Scheme 2.21). 
Due to the low solubility of the vinyl prodrug 26 in acetonitrile, the reaction was 
carried out in a mixture of CH3CN/CH3OH/H2O (4:5:1), using tetrazine 25 (10 mM) 
with the vinyl prodrug 26 (0.5 mM). The disappearance of the prodrug 26 peak was 
observed over 5 days, alongside an increase of the corresponding product 24 and 
CPT (Figure 2.21). 
Prodrug–prodrug activation was verified in PC3 cells by incubating the two prodrugs 
25 and 26 at 37 °C for 3 days. Co-treatment of 26 (0.5 µM) and the tetrazine 25 (10 
µM) induced cell death comparable to treatment with the “free” CPT, confirming the 
in situ formation of the two active parental drugs (Figure 2.22). 
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Figure 2.21. A) Dual drug activation reaction of an excess of the tetrazine prodrug 25 and 
camptothecin derivative 26. B) HPLC (λ = 350 nm) analysis of the reaction between tetrazine 
25 and vinyl prodrug 26 using resorufin as an internal standard (after 5 days). A reduction > 
85% of the vinyl prodrug 26 peak was observed after 5 days. The unlabelled peaks 
correspond to the decomposition products of the tetrazine 25. 
 
Figure 2.22. PC3 cancer cells were incubated with tetrazine 25 (10 µM), vinyl prodrug 26 
(0.5 µM), 25 (10 µM) together with 26 (0.5 µM), and CPT (0.5 µM). Cell viability was 
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2.7 Conclusions and future work 
 
A new strategy is demonstrated that offers a new paradigm in prodrug activation, 
where a tetrazine is not only used as trigger but at the same time as a “protecting 
group” for a bioactive pyridazine. This strategy was validated showing the 
simultaneous use of a tetrazine as a trigger to de-mask a protected anti-cancer drug 
(camptothecin) and as a protecting group for a pyridazine-based microRNA-21 
inhibitor 24.96 Specifically, the free hydroxyl group of the camptothecin was 
protected with a vinyl ether moiety, and the miRNA-21 inhibitor 24 was masked as a 
tetrazine scaffold. The reaction between the tetrazine prodrug 25 and the vinyl ether 
of protected drug 26 led to the formation of the active corresponding drugs, the 
miRNA-21 inhibitor 24 and the free camptothecin (CPT), without the formation of 
any by-products (except for the loss of nitrogen). 
Drug activation occurs without the use of any catalyst, in a traceless fashion, fully 
respecting the bioorthogonality criteria. It is worth noting that this strategy activates, 
alongside a conventional anti-cancer drug, a miRNA-21 inhibitor. Knocking down 
oncogenic miRNA which is often linked with drug resistance in cancer cells thus 
provides new possibilities in the field of combination therapy (utilising two or more 
drugs), potentially addressing the issue of drug resistance. 
The vinyl ether has been demonstrated to be a good partner in the IEDDA with 
tetrazines, with its advantages including small size, and ease of installation 
compared to other dienophiles (such as TCO) and good robustness. Although the 
vinylation reaction was challenging, the protection of the free hydroxy group CPT 
with the vinyl ether improved the solubility of the drug itself and its stability,97, 98 
potentially helping more of the active drug reach the target site.  
Future work will consist of screening other well-known anticancer drugs (such as 
etoposide, doxorubin, topotecan), bearing not only hydroxy but also amino 
functionalities, as well as other pyridazine-based drugs. In fact, pyridazines are 
common scaffolds found in many natural products and several therapeutics, e.g. 
apresoline, sulfamethoxypyridazine and cadralazine (Figure 2.23),99 and therefore 
the prodrug–prodrug activation process could be applied to the combination of 













3. Tetrazine-activated “turn-on” probe 
 
This work was carried out in collaboration with Y. Zhang and parts of this chapter 
have been submitted for publication as “Multifunctional, Histidine-tagged Polymers: 
Antibody Conjugation and Signal Amplification” by Y. Zhang,† A. Gambardella,† M. 
Ucuncu, J. Geng, A. Lilienkampf and M. Bradley (submitted to Angewandte 
Chemie). 
 
3.1. Fluorogenic probes 
 
Fluorescent imaging technologies have been enormously beneficial in allowing a 
detailed understanding of many biological processes. Some of the first examples of 
protein labelling in vivo were achieved using genetically encoded green fluorescent 
proteins (GFPs), in which the fluorescent protein (FP) is fused to a protein of 
interest. This approach has enabled both the localisation and quantification of 
proteins to be determined and has been used for exploring protein–protein 
interactions and trafficking inside cells and organisms.100 However, fluorescent 
proteins are large in size (~ 30 kDa) and can interfere or perturb biological functions 
and expression.101, 102 Moreover, the labelling strategy requires genetic 
manipulations and cannot be used to image biomolecules that are not directly 
genetically encoded, e.g. glycans or lipids. 
An alternative labelling approach utilises small-molecule (< 0.5 kDa) dyes that offer 
enhanced photophysical properties, e.g. brightness, wavelength choice and 
photostability, while minimising possible perturbation of the natural behaviour of the 
protein of interest.103 In this field, bioorthogonal chemistry has been extensively used 
where the protein of interest is modified with a bioorthogonal functionality, e.g. an 
azide, alkene or alkyne and treated with an excess of a bioorthogonal fluorescent 
counterpart (Figure 3.1).70, 71, 104 However, extensive washing steps are typically 
required to reduce background fluorescence related to non-conjugated adsorbed 
dye. As such it is not suitable for many intracellular applications.105  
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Figure 3.1. Representation of the most commonly used bioorthogonal reactions for labelling. 
 
A complementary and more efficient approach to minimize the background 
fluorescence utilises fluorogenic probes, sometimes called “smart probes”, in which 
the fluorescence of the probe is quenched, and “activated” or “switched-on” upon 
specific binding or conjugation with the target site, potentially allowing imaging in 
vivo without washing steps.105, 106  
The condensation of aldehydes/ketones with hydrazines/alkoxyamines to form 
hydrazones/oximes represents one of the first examples of a bioorthogonal 
transformation applied to intracellular protein labelling.107, 108 Several hydrazine and 
alkoxyamine-functionalised probes have been reported, whose fluorescence is 
quenched by internal charge transfer (ICT)109 processes and restored upon reaction 
with ketones or aldehydes (Figure 3.2). Despite their use as chemical reporters, the 
slow reaction rates (< 10−3 M−1 s−1) and the need for high concentrations of the 
reactants to obtain good labelling, can result in high background fluorescence and 
toxicity. Moreover, the acidic conditions (pH = 4–6) required for the reaction, and 






Figure 3.2. Hydrazine/alkoxyamine-functionalized fluorescent probes showing an increase in 




In 2000, chemical reporters bearing non-natural functional groups, such as azides, 
were explored in order to avoid undesirable cross-reactivity with endogenous 
molecules, with the Staudinger ligation overcoming some of the previously 
mentioned limitations.111 Bertozzi reported a coumarin-phosphine probe 42 in which 
its fluorescence was quenched by the lone pair on the phosphorous and restored 
upon Staudinger ligation with the azide 43 (Figure 3.3).112  The applicability of this 
probe for biomolecule labelling was evaluated by reacting the phosphine probe 42 
with an azido-functionalised recombinant murine dihydrofolate reductase (mDHFR). 
The results showed that only the azido-mDHFR was efficiently labelled, resulting in 
an increase in fluorescence of 60-fold upon the Staudinger ligation. Although this 
reaction showed higher reaction rates compared to that of oxime formation, the rate 
is still slow (~10−3 M−1 s−1) and thus, it is necessary to use high concentration of 
reactants (> 250 µM). Additionally, the phosphine probes are prone to non-specific 






Figure 3.3. Coumarin-phosphine 42 dequenched upon Staudinger ligation with an azide, 
resulting in a 60-fold increase in fluorescence. The lone pair on the phosphorus is 
responsible for the ICT quenching of the coumarin fluorescence that is restored upon 
phosphine oxidation.  
 
Later on, the same group reported an improved phosphine probe with activation by 
Staudinger ligation in which fluorescence dequenching relies on Förster resonance 
energy transfer (FRET), and was used for the detection of azido-functionalised 
glycoproteins on living cells.113 In this work, the fluorescein-phosphine probe 45 was 
directly attached to Disperse Red-1 46 that acts as intramolecular quencher through 
a FRET mechanism. The Staudinger reaction between the probe 45 and an azide 
results in the release of the quencher which restores the fluorescence of the 
fluorophore (Figure 3.4). The suitability for biomolecule labelling was tested again 
with azido-mDHFR, showing selective labelling upon incubation with the phosphine 
probe 45 with an increase in fluorescence of 170-fold. This reaction was also 
evaluated when HeLa cells were incubated with N-α-azidoacetylmannosamine 
(Ac4ManNAz) with phosphine probe 45. The results showed efficient cell-surface 
labelling of the azido-functionalised HeLa cells and, unlike the previously reported 
coumarin-phosphine probe 42, showed little non-specific background fluorescence. 
However, the applicability of this probe is restricted to cell-surface labelling. 
Although several improvements of Staudinger-activated probes have been reported, 





Figure 3.4. Fluorogenic fluorescein-phosphine probe 45 in which the fluorescence is 
quenched via a FRET mechanism. The Staudinger reaction with an azide-functionalised 
biomolecule leads to the release of the quencher (Disperse Red-1) and switching on of 
fluorescence. However, again the phosphine can react with oxygen and the ester will be 
cleaved rapidly. 
 
The first example of a fluorogenic azide-probe was described by Wang with a 
“clicking-and-probing” strategy, in which a fluorescent probe is formed upon a 
CuAAC reaction.114 Eight pro-fluorophores were synthesised with the coumarin motif 
modified at position 3- or 7- with an azide group in order to quench its fluorescence. 
The reaction between the azide with terminal alkynes led to the formation of highly 
fluorescent 1,2,3-triazole (Figure 3.5). The most promising pro-fluorophore, 3-azido-
7-hydroxycoumarin (48), was used for the selective labelling of newly synthesised 






Figure 3.5. First example of bioorthogonal reaction applied for the formation of a fluorogenic 
probe 49. The introduction of azido moiety on the coumarin quenches its fluorescence that is 
restored upon 1,2,3-triazole formation. However, azido-coumarins often suffer of low stability 
in oxidative conditions. 
 
Several dyes, such as 1,8-naphthalimide, fluorescein and Si-Rhodamine (Oregon 
Green), have been synthesised and decorated with azides, however, aryl azides can 
undergo degradation pathways in biological systems resulting in a premature switch-
on of a probe’s fluorescence. 105, 106  
Cravatt117 and Fahrni118 reported fluorogenic probes for CuAAC reaction in which 
rhodamine and coumarin derivatives were functionalised and quenched by the 
installation of an alkyne moiety (Figure 3.6). In particular, Cravatt reported the so-
called activity-based protein profiling (ABPP) in vitro and in mice by administration of 
azide-phenyl sulfonate 50 (20 mg/kg) and treatment with the rhodamine-alkyne tag 
51 (Figure 3.6). Despite their use for the detection of azide-functionalised targets in 
vitro and in vivo, the background fluorescence observed caused by azide-phenyl 
sulfonate 50 was still high. Furthermore, copper (I) species are cytotoxic, thus, 





Figure 3.6. Enzyme labelling via alkylation followed by a copper-catalyzed click reaction 
using a rhodamine-alkyne fluorescent probe 51. 
 
This was followed by fluorogenic probes activated by “copper-free click chemistry” 
(52 and 53), SPAAC (strain-promoted alkyne-azide cycloaddition), reported by 
Bertozzi, in which a fluorogenic probe was generated by fusing 
biarylazacyclooctynone (BARAC) to an alkyne-coumarin scaffold 52 (Figure 3.7). 
Reaction with 2-azidoethanol gave an increase in fluorescence of 10-fold, however it 
exhibited a low fluorescence quantum yield and required excitation at 300 nm, a 
wavelength not suitable for many biological applications.  
 
 
Figure 3.7. Examples of alkyne-functionalised smart probes in which the fluorescence is 




Recently, Boons reported the use of 4-dibenzocyclooctynol derivative (Fl-DIBO) 55 
as a fluorogenic click reagent for labelling azide-functionalised targets. Efficient 
protein labelling with Fl-DIBO was evaluated by performing the reaction with an 
azide-modified bovine serum albumin 56 (BSA) (Figure 3.8). When Fl-DIBO and 
azide-BSA were incubated, they observed the formation of triazole cycloproduct 57 
with a turn-on in fluorescence of  more than 1000-fold increase compared to 
unreacted probe 55.102 However, cyclooctyne derivatives can be attacked by 
nucleophiles present in cellular environment, such as cysteine and glutathione, and 
therefore are not fully compatible with in vivo labelling, nor are the wavelengths 
optimal for biological applications.21, 119  
 
Figure 3.8. Switch-on of fluorescence of the Fl-DIBO fluorogenic probe 55 via strain-
promoted alkyne-azide cycloaddition (SPAAC) with an azide-tagged BSA 56, resulting in the 
formation of the highly fluorescent triazole 57. 
 
More recently, IEDDA reactions with tetrazines have been exploited in the field. 
Tetrazine’s chemistry has a few advantages as their reactions with strained 
dienophiles have fast reaction rates (up to 105 M−1 s−1) and in addition, tetrazines 
are chromophores that absorb between λ = 500–560 nm, which makes them perfect 
candidates as quenchers towards several fluorophores via a FRET mechanism. 
Weissleder firstly exploited tetrazine-fluorogenic probes, reporting a series of 
tetrazine-quenched boron-dipyrromethenes (BODIPY) and xanthanes in which their 
fluorescence could be restored upon tetrazine ligation with a trans-cyclooctene 
(Figure 3.9).120 They modified the position C7 of taxol with trans-cyclooctene and 
incubated PtK2 cells with modified taxol 58. After washing, the cells were treated 
with tetrazine-quenched BODIPY 59. The reaction led to the rapid formation of the 





Figure 3.9. Tetrazine fluorogenic probe 59 in which the tetrazine acts as quencher via a 
FRET mechanism. The fluorescence is restored upon IEDDA reaction with a TCO-modified 
taxol, resulting in an increase in fluorescence of some 20-fold. 
 
Chin used tetrazine-quenched fluorophores (fluorescein, BODIPY and 
tetramethylrhodamine (TAMRA)), for the site-specific labelling of genetically 
encoded norbornene-containing amino acids in E. coli and on the surface of 
mammalian cells.121 The reaction proceeded rapidly (complete in 2 hours) using low 
concentration of the tetrazine-probe 61 (200 nM) albeit the fluorescence increase 
was just of 5-10 fold (Figure 3.10). Although these probes have great potential, the 





Figure 3.10. Site-specific labelling of proteins GFP (modified with a norbornene moiety) with 
tetrazine–TAMRA fluorogenic probe 61 reaction.  
 
The efficiency of FRET fluorescent probes crucially depends on the orientation of 
the transition dipole moment and on the separation of the chromophores (usually 2–
10 nm), however, applications of FRET with chromophore distance beyond this 
range (> 10 nm) have been recently reported.122 In order to improve the turn-on 
ratios of tetrazine fluorogenic probes, Weissleder designed new tetrazine-BODIPY 
probes (64–66) with a minimal distance between the tetrazine core and BODIPY 
scaffold (Figure 3.11).123 Upon reaction with trans-cyclooctenol in acetonitrile, these 
probes exhibited exceptionally high turn-on ratios (more than 100-fold increase in 
fluorescence). To explain the incredibly high fluorescence turn-on ratios, Weissleder 
proposed that alongside FRET, another mechanism, that of through-bond energy 
transfer (TBET),124, 125 was also involved in quenching the fluorescence of these 
probes. To demonstrate that TBET was playing a crucial role as a quenching 
mechanism for these probes, Weissleder synthesised a tetrazine-BODIPY probe 65 
in which the transition dipoles of the BODIPY and tetrazine were nearly 
perpendicular, preventing FRET quenching from occurring. Upon reaction with 
trans-cyclooctenol 120-fold fluorescence increase was observed, suggesting the 
TBET was the main quenching path for these probes. However, further 
investigations are still required to confirm the quenching process and to exclude 





Figure 3.11. Reported fluorescence increases for TBET-based tetrazine–BODIPY 
fluorogenic probes by Weissleder. 
 
Since TBET mechanism does not require overlapping of absorption and emission 
bands of the two chromophores, a series of rigidly-linked tetrazine probes, from 
green to red-emitting wavelengths, were synthesised by Weissleder and 
Wombacher and applied for the detection of TCO-modified proteins and 
biomolecules in living cells (e.g.  Escherichia coli dihydrofolate reductase (eDHFR), 
bovine serum albumin (BSA) and the epidermal growth factor receptor (EGFR)).51, 
54, 126 
In the past few years, the library of available tetrazine fluorogenic probes has greatly 
expanded, with probes available accross the entire visible spectrum, from blue to 
NIR (Figure 3.12), but still, the great potential showed by tetrazines as fluorescent 
quenchers and bioorthogonal reactants is driving researchers to synthesise and 





Figure 3.12. Examples of blue to red emitting TBET-based tetrazine smart probes showing 
reported high turn-on ratios upon IEDDA reaction (adapted from Wombacher et. al. Chem. 
Sci. 2017, 8, 1506). Blue-emitting probe reported by Weissleder,
126
 green to red-emitting 

















3.2 Project aims 
 
Throughout the past decades, fluorogenic probes have being greatly exploited as 
powerful tool for labelling applications, overcoming issues of traditional fluorescent 
tags or markers, which often require extensive washing steps to remove the 
accumulated, untargeted and unreacted tag. Tetrazine fluorogenic probes have 
allowed site-specific labelling of several biomolecules (e.g. proteins, lipids, glycans) 
in vitro and in vivo.21, 34, 106 Still, one of the major challenges in imaging approaches 
is to minimise background fluorescence, especially for in vivo applications where 
background autofluorescence is often high. Therefore, there is high demand for the 
development of alternative approaches that could increase fluorescence signals, 
leading to greater signal-to-noise ratios. It was envisioned that the fluorescence 
signal could be amplified by combining a fluorogenic tetrazine probe with a reaction 
partner bearing multiple dienophiles as an active site for a multiple IEDDA reactions.  
The focus of this work was the synthesis and investigation of three tetrazine-
quenched fluorophores and their reaction with polymers “loaded” with norbornene 
moieties as an effective amplification “switch-on” system. It was evaluated in vitro 
and on cells targeted/labelled with an antibody (Figure 3.13).  
 





3.3 Synthesis of tetrazine-quenched fluorophores 
 
An essential requirement for the design of a fluorogenic probe is that fluorescence 
has to be fully quenched, but rapidly “switched-on” upon reaction. Since Weissleder 
reported a series of ultrabright fluorogenic tetrazine-coumarin probes showing turn-
on ratios up to 11,000-fold upon IEDDA reaction with TCO-modified targets,126 
coumarin was initially selected as a fluorophore for this study. Coumarins are blue 
emitting dyes, small in size. The tetrazine fluorogenic probe 67 was designed 
(Figure 3.14) inspired by the work of Wombacher and Weissleder in which the 
importance of tetrazine–fluorophore proximity was highlighted for maximising the 
“switch-on” in fluorescence.51, 54, 123 As discussed in the previous sections, tetrazine 
reactivity can be modulated by choosing the appropriate substituents in positions 3- 
and 6- on the aromatic ring. An asymmetric tetrazine bearing an electron-
withdrawing group (EWG) showed enhanced reactivity, with 6-methyl-3-pyridyl-
1,2,4,5-tetrazine displaying a good balance between hydrolytic stability and 
reactivity under biological conditions.21, 28, 29 Therefore, it was envisaged that 
conjugation between the tetrazine scaffold and the coumarin through a pyridine 
moiety could potentially induce quenching via FRET and TBET mechanisms, and 
simultaneously improve the reactivity and the stability of the tetrazine core. 
 
Figure 3.14. Retrosynthesis of tetrazine-quenched coumarin probe 67. 
 
Starting from commercially available 7-amino-4-methylcoumarin 70 (λex = 365 nm 
λem = 440 nm in EtOH) modification on the amino group was carried out by a slightly 
modified Buchwald–Hartwig coupling protocol using 2 mol% Pd(OAc)2, 2 mol% rac-
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (rac-BINAP) as a ligand, and potassium 




irradiation (µW) at 180 °C, with screening of different reaction times undertaken in 
order to optimise the reaction (Table 3.1). The best result was obtained when the 
reaction was irradiated at 180 °C (µW) for 90 minutes (Entry 3). The product 68 was 
isolated by precipitation in 71% yield without further purification needed. 
 
Table 3.1. Screening of different conditions for the synthesis of coumarin precursor 68. 
 
Entry Time Yield% 
1 30 min - 
2 60 min 30% 
3 90 min 71% 
 
 
Several reaction conditions were then screened for the synthesis of the asymmetric 
tetrazine 67 starting from the coumarin precursor 68 (Table 3.2). Initially, standard 
Pinner conditions were trialled using excess hydrazine monohydrate, acetonitrile, 
and heating at 90 °C for 18 hours. However, no conversion was observed and 
starting material was recovered. The Pinner reaction was then performed using 
microwave irradiation (µW) at various temperature and times (Table 3.2). 
Unfortunately none of these attempts were successful with the starting material 








Table 3.2. Screening of reaction conditions for the synthesis of tetrazine 67. 
 
Entry NH2NH2 CH3CN Temp. Time. Conversion%
[a]
 
1 8 eq. 5 eq. 90 °C 18 h 0 
2 20 eq. 5 eq. 90 °C 18 h 0 
3 8 eq. 5 eq. 40 °C
[b]
 30 min 0 
4 8 eq. 5 eq. 40 °C
[b]
 1 h 0 
5 8 eq. 5 eq. 70 °C
[b]
 1 h 0 
6 8 eq. 5 eq. 70 °C
[b]
 1 h 0 
7 8 eq. 5 eq. 90 °C
[b]






 µW irradiation. 
 
These results can be explained by the poor reactivity of the nitrile group, which 
prevents formation of the product. In order to improve the electrophilicity of the nitrile 
group, the metal-catalysed Pinner approach was attempted for the synthesis of 
tetrazine–coumarin 67 (Scheme 3.1). The reaction was performed using hydrazine 
monohydrate, acetonitrile, heating at 60 °C for 24 hours, with the addition of either 
zinc or nickel triflates as Lewis acids.  
 
Scheme 3.1. Attempted synthesis of tetrazine-coumarin probe 67 via metal-catalysed Pinner 
reaction. 
 
Unfortunately, those conditions were also not successful, hence the synthesis of this 
tetrazine–coumarin was no longer pursued and an alternative solution was sought 
with attention focussed on the synthesis of reported tetrazine–BODIPY fluorogenic 






Figure 3.15. Structure of tetrazine fluorogenic probes 64 and 71 selected, with reported turn-
on ratios of 1600- and 12-fold when reacted with TCO derivatives. 
 
The synthesis of tetrazine 64 was first attempted following the literature procedure of 
Weissleder,123 where BODIPY-nitrile precursor 72 was obtained in a one-pot 
procedure starting with commercially available 3-formylbenzonitrile 73 and 
dimethylpyrrole in the presence of trifluoroacetic acid (TFA). The reaction was 
stirred under argon atmosphere in presence of TFA for 18 hours. Subsequent 
oxidation was performed by addition of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(DDQ) (Scheme 3.2). After 30 minutes, the m-cyanophenyl-BODIPY 72 was 
obtained by addition of Hünig base (DIPEA) and boron complexation with BF3·OEt2 
in very low yield (3%). The synthesis of the corresponding tetrazine–BODIPY 64 
was attempted using the zinc-catalysed Pinner reaction protocol,48 but, 
unfortunately, only starting material 72  and traces of side-product 74 were observed 
by 1H NMR spectroscopy. A possible explanation is that while the use of DMF as co-
solvent helps the solubility of the reagents, it can also react with hydrazine leading 
to the formation of the asymmetric tetrazine 74, bearing H as second substituent 





Scheme 3.2. Unsuccessful strategy attempted for the synthesis of tetrazine fluorogenic 
probe 64.  
 
In order to avoid the formation of by-products and to increase the yield of the 
reaction, another strategy was attempted for the synthesis of tetrazine–BODIPY 64 
(Scheme 3.3). The BODIPY precursor 64 was synthesised via condensation of 3-
formylbenzonitrile 73 with dimethylpyrrole  promoted by a mild Lewis acid, InCl3.
127 
The intermediate 75 was directly oxidised using DDQ to give the product 76 in a 
moderate yield (56%). With the dipyrrole derivative, the formation of the BODIPY 
scaffold was attempted using stoichiometric amount DIPEA and BF3·OEt2. 
Unfortunately, monitoring the reaction by 1H NMR spectroscopy showed low 
conversion to the product 72 (17%) even after 18 hours. However, using a large 
excess of DIPEA and BF3·OEt2, it was possible to improve the yield to 40%. The 
synthesis of the desired tetrazine 64 was attempted using both nickel and zinc as 
Lewis acid for Pinner-catalysed reaction,48 but, once again only decomposition of 72 





Scheme 3.3. Alternative synthetic route for the synthesis of tetrazine probe 64. 
 
Since installation of the tetrazine scaffold was somehow inhibited, it was envisaged 
that an alternative synthetic strategy would be formation of tetrazine motif before the 
formation of the BODIPY moiety. Tetrazine-BODIPY 64 was then synthesised in 
three steps starting from the commercial available 3-(hydroxymethyl)benzonitrile 77 
(Scheme 3.4). The nickel-catalysed Pinner reaction with hydrazine monohydrate 
and acetonitrile was followed by oxidation with (diacetoxyiodo)benzene which 
provided the tetrazine 78 in 41% yield over two steps. The oxidation of the benzylic 
alcohol was achieved using Dess–Martin periodinane (DMP) resulting in the 
formation of the tetrazine-aldehyde precursor 79 in 80% yield.54 The final step, the 
construction of the BODIPY scaffold, was then achieved via a one-pot strategy 
starting with the condensation of tetrazine 79 with the dimethylpyrrole in presence of 
TFA. A subsequent oxidation with DDQ, addition of DIPEA and complexation with 
and BF3·OEt2 gave the desired tetrazine–BODIPY 64 in 38% yield over three steps. 
This strategy not only provided the product in much higher yield than the previously 
reported protocol (8.6%), but also avoided the formation of unnecessary by-products 





Scheme 3.4. New practical synthetic strategy for the synthesis of tetrazine-BODIPY 64. 
 
The second tetrazine–BODIPY probe 71 was synthesised according to a literature 
procedure,51 starting with the formation of iodotetrazine 80 by a nickel-catalysed 
Pinner reaction with acetonitrile and hydrazine monohydrate, heating at 60 °C 
overnight, giving the tetrazine 80 in 30% yield. The fluorogenic probe 71 was then 
synthesised by reacting tetrazine 80 with acetylene-BODIPY 82¥ via Sonogashira 
cross-coupling reaction using 5 mol% of CuI and 5 mol% of Pd(Ph3)2Cl2 catalyst to 
provide the tetrazine-quenched BODIPY 71 in 57% yield (Scheme 3.5). 
 
Scheme 3.5. Synthesis of tetrazine fluorogenic probe 71 following a literature procedure.
51
 
                                                          
¥




3.4 Reactivity and stability  
 
Once the fluorogenic probes 64 and 71 were synthesised, their reactivity was 
evaluated by monitoring the reaction with a multi-decorated norbornene polymer 83¶ 
via fluorescence spectroscopy (Figure 3.16–3.18). The polymer was designed to 
bear multiple reactive centres (an average 8 norbornene moieties per polymer 
chain) in order to achieve fluorescence “switch-on” and signal amplification. The 
reaction was performed in PBS with the time-dependent increase in fluorescence 
followed when the tetrazines 64 or 71 (0.5–2 µM) were incubated with the polymer 
83 (12 µM) at 37 °C. Both tetrazine 64 and 71 showed a high increase in 
fluorescence with up to 24- and 10-fold increase after 30 minutes (Table 3.3), and 
increasing to 41-fold for tetrazine 71 after 2 hours. 
Table 3.3. Fluorescence increase (F.I.) of the reaction between 64 or 71 (0.5–5 μM) and 
polymer 83 (12 μM) in PBS, measured over time (30, 60 and 120 min). 
Tz 64  F.I.
[a]



















1 µM 10-fold 10-fold 10-fold 1 µM 24-fold 30-fold 41-fold 
2 µM 9-fold 10-fold 10-fold 2 µM 15-fold 23-fold 36-fold 
5 µM 4-fold 9-fold 10-fold 5 µM 4-fold 11-fold 16-fold 
[a] 
The fluorescence intensities monitored at λex = 488 nm and λem = 511 nm and fold increase 
calculated comparing the fluorescence intensities at t = 0 (before the incubation of the 
polymer 83) 
                                                          
¶





Figure 3.16. Reaction between polymer 83 (12 µM) and tetrazine fluorogenic probe 64 and 
71 (λex = 488 nm) inducing a “switch-on” and amplification in fluorescence signal upon 




























































































































Figure 3.17. Fluorescence spectra of the reaction between tetrazine-BODIPY 71 (0.5–2 µM) 
and the polymer 83 monitored over time at 37 °C.  



















































































































Figure 3.18. Fluorescence spectra of the reaction between tetrazine-BODIPY 64 (0.5–2 µM) 




The stability of tetrazines 64 and 71 was evaluated in PBS, in cell culture media 
(containing 10% of fetal bovine serum (FBS)) and in serum-free media (without 
FBS) (Figure 3.19). While both the tetrazine 64 and 71 exhibited good stability in 
PBS and in serum-free media, in cell culture media tetrazine 64 was not stable, 
showing a “switch-on” in fluorescence. This was attributed to the destruction of the 
tetrazine core by biological nucleophiles in FBS and therefore tetrazine 71 was 



















































                  





























Figure 3.19. Stability studies of tetrazine probes 64 and 71 (1 µM) in PBS at 37 °C, serum-
free media, cell culture media (10% FBS) conducted in black 96-well plate. The fluorescence 
intensity was monitored (λex= 465 and 505 nm, λem= 508 and 548 nm, respectively), with 









3.5 Fluorescence amplification§ 
 
The reaction between tetrazine 71 and the polymer 83 was evaluated in vitro to 
demonstrate its suitability for protein labeling. For this purpose polymer 83 was 
conjugated to BSA (85, see Supporting Figures) via an amidation reaction, in which 
the ω-carboxylic acid of the polymer was activated via reaction with EDC/NHS to 
give corresponding NHS ester that was subsequently reacted with BSA to give the 
polymer–BSA conjugate 85 (see Supporting Figures). The reaction of polymer–BSA 
85 was evaluated in the IEDDA reaction with tetrazine 71 and analyzed by SDS-
PAGE (Figure 3.20). No fluorescence was observed when tetrazine 71 was 
incubated with only BSA, whereas a strong fluorescent band was observed when 
the polymer–protein conjugate 85 (2.5 µM) was treated with tetrazine 71 (25 µM), 
showing the effective labelling with high selectivity. 
 
Figure 3.20. A) The reaction between tetrazine-quenched BODIPY 71 and the polymer–BSA 
conjugate 85 performed in PBS at 37 °C, resulting in the simultaneous “switch-on” and 
amplification in fluorescence. B) SDS-PAGE image of polymer–BSA labelling: MW Markers: 
                                                          
§ 




Precision Plus Protein™ Kaleidoscope™ Prestained Protein Standards, 10-250 kDa; Lane 1: 
BSA; Lane 2: BSA (2.5 μM) incubated with tetrazine 71 (25 μM); Lane 3: polymer–BSA 
conjugate 85; Lane 4: polymer–BSA conjugate 85 (2.5 μM) incubated with tetrazine 71 (25 
μM) (data acquired by Y. Zhang).  
 
Herceptin (also called Trastuzumab) is a clinically used antibody used for treatment 
of breast cancer, in which the epidermal growth factor receptor HER2 is up 
regulated.128 Therefore, the polymer 83 was conjugated to Herceptin (polymer–
Herceptin 86), using the same strategy described for the conjugation with BSA, and 
its reaction with tetrazine–BODIPY 71 was investigated and monitored by SDS-
PAGE gel (Figure 3.21). 
Fluorescent bands were completely absent when tetrazine 71 was incubated only 
with Herceptin, whereas a strong fluorescent band was observed upon co-treatment 
with polymer–Herceptin 86 (2.5 µM) and tetrazine 71 (25 µM), indicating specific 
and selective labelling.  









Figure 3.21. A) Representation of the reaction between tetrazine-quenched BODIPY 71 and 
polymer–Her conjugate 86 performed in PBS (pH = 7.4) at 37 °C, resulting in the 




polymer–BSA labelling: MW Markers: Precision Plus Protein™ Kaleidoscope™ Prestained 
Protein Standards, 10-250 kDa; Lane 1: Herceptin (Her); Lane 2: Her (2.5 μM) incubated 
with tetrazine 71 (25 μM); Lane 3: polymer–Her conjugate 86; Lane 4: polymer–Her 
conjugate 86 (2.5 μM) incubated with tetrazine 71 (25 μM). Staining was carried out with 
Coomassie blue (0.1% w/v in 1:4:5 AcOH/H2O/CH3OH for 2 hours) (data acquired by Y. 
Zhang).   
 
3.6 Fluorescence amplification on cells§ 
 
For the cells study, the breast cancer cell line (SK-BR-3) known to overexpress 
HER2 was used. To demonstrate the amplification in fluorescence signal, the 
antibody Herceptin conjugated to BODIPY (BODIPY–Herceptin 87, see Supporting 
Figures)¥, was used as a control. The cytotoxicity of the tetrazine 71, the polymer 86, 
the BODIPY–Herceptin conjugate 87 and Herceptin were also evaluated on SK-BR-
3 cells (MTT assay, Figure 3.22). Cellular incubation of native antibody Herceptin 
(up to 20 nM), BODIPY–Herceptin conjugate 87 (up to 50 nM), tetrazine 71 (up to 2 
µM) or the polymer–Herceptin conjugate 86 (up to 50 nM) did not show any 
significant reduction in cell viability (> 90%). Therefore, these concentrations were 
used to further evaluate the amplification method on cells (Figure 3.22). 
 



























































































Figure 3.22. SK-BR-3 cell were incubated with: A) Herceptin (0–50 nM); B) BODIPY-Her 87 
(0–50 nM); C) tetrazine 71 (0–5 µM); D) Polymer-Her 86 (0–50 nM). Cell viabilities were 
measured after 24 hours after incubation (MTT assay, n =3) A HER2 receptor negative 
cancer cell line MCF-7 was used as a negative control (data acquired by Y. Zhang).   
 
The fluorescence “switch-on” and amplification were tested on SK-BR-3 cells and 
analysed by flow cytometry and fluorescent spectroscopy (Figure 3.23 and 3.24). No 
significant fluorescent increase was observed upon cellular incubation with the 
antibody or the polymer–Herceptin conjugates 86, whereas a 3-fold increase in 
fluorescence was observed when the cells were treated with BODIPY-Herceptin 87 
(10 nM). However, cellular incubation of the polymer–Herceptin conjugate 86 (10 nM) 
for 4 hours followed by treatment with tetrazine-quenched BODIPY 71 (1 µM) for 30 
minutes showed a 47-fold increase (Figure 3.23), confirming the simultaneous 
“switch-on” and amplification. To evaluate if the fluorescence increase could be 
tuned by changing the norbornene densities on the polymer chain, the polymer–
Herceptin conjugate 88¥ was synthesised (bearing an average of 21 norbornenes 
per polymer chain, see Supporting Figures). Upon cellular incubation of the 
polymer–Herceptin conjugate 88 (10 nM) for 4 hours followed by treatment with the 
tetrazine-quenched BODIPY 71 (1 µM) for 30 minutes a great fluorescence increase 
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was observed (83-fold, Figure 3.23), confirming that the amplification of signal could 




















































Figure 3.23. Flow cytometry histograms of SK-BR-3 cells treated with the BODIPY–Her 87 
(10 nM orange), tetrazine 71 (1 μM, blue), and co-treatment with polymer–Her conjugates 86 
(10 nM) and tetrazine 71 (1 μM, green), and untreated cells used as control (red) (data 









Figure 3.24. Confocal fluorescence microscopy images of SK-BR-3 cells treated with 
BODIPY–Her (10 nM) or polymer-Her conjugates 86 or 88 (10 nM) then with tetrazine 71 (1 
μM) and untreated cells as a control. The panels show from left to the right (i) cell nuclei 
(blue, λex/em = 353/483 nm), (ii) “switched-on” BODIPY (green, λex/em = 488/512 nm) (iii) the 
plasma membrane (red, λex/em = 649/666 nm) and (iv) and merged images. Scale bar = 10 














3.7 Conclusions and future work 
 
Several synthetic pathways were attempted in order to synthesise new fluorogenic 
probes in which the tetrazine core was directly conjugated to the fluorophore 
scaffold, in order to modulate its reactivity and fluorescent properties. Screening of 
different reaction conditions (e.g. catalyst, temperature, solvent) was still required for 
the synthesis of new tetrazine fluorogenic probes with minimal distance between the 
tetrazine scaffold and the fluorophore. As a proof of concept for the amplification 
strategy, coumarin and BODIPY probes were first investigated for this study. 
However, the incorporation of fluorophores emitting in the NIR region (700–900 nm) 
could provide several advantages for in vivo labelling (e.g. minimal tissue scattering 
and autofluorescence, resulting in high signal-to-noise ratios). Despite the synthetic 
challenges, a new fluorescent amplification method was developed that involves the 
reaction between a tetrazine-quenched fluorophore (BODIPY) with a 
multinorbornene-functionalized polymer, allowing activation and amplification of the 
fluorescent signal. The reaction between the tetrazine probe and the norbornene 
polymer was evaluated and applied to the selective labeling of proteins (BSA) and 
an antibody (Herceptin). This strategy was applied on cells, where the norbornene 
polymer was conjugated to the clinically used antibody Herceptin and was applied to 
the selective labeling of breast cancer cells. A fluorescence increase of some 80-
fold greater than a conventional fluorophore-labelled antibody using the same 
fluorescent moiety was demonstrated using the polymer–Herceptin conjugate. This 
improvement in the fluorescence signal could potentially contribute to the 
development of new techniques for cancer diagnostics and for image guided 
surgery, helping the visualisation of low abundance targets. The amplification effect 
can be exploited in many other biomedical applications, for example in drug delivery, 
for the simultaneous release of multiple cargos, pre-targeted radioimmunoimaging 
and radiotherapy approaches. For instance, the tetrazine core can be loaded with a 





4. Tetrazine-labile protecting group for solid-phase 
synthesis 
 
This work was done with Dr M. Staderini and parts of this chapter are published in: 
M. Staderini,† A. Gambardella,† A. Lilienkampf, M. Bradley Organic Letters, 2018, 
20, 3170-3173. 
 
4.1. Solid-phase synthesis 
 
Peptides are involved in numerous physiological and biological processes and have 
been used as therapeutics since the isolation of insulin in the 1920s. More than 60 
peptides have been FDA-approved as drugs and more than 300 peptides are 
currently in clinical and pre-clinical studies.129, 130 Among those, a great number 
consist of cyclic peptides derived from natural products, such as hormones (e.g. 
oxytocin), and antibiotics (e.g. polymyxins). Cyclic peptides offer numerous 
advantages compared to their linear counterparts, typically showing higher target 
affinity and selectivity and higher stability to enzymatic degradation.131,132 Some 
peptide-based drugs include cyclosporine A and caspofungin used as 
immunosuppressants and antifungals respectively (Figure 4.1).133 The increasing 
demand for these compounds has driven researchers to seek for novel protocols 
and approaches to their synthesis.  
A breakthrough in producing peptides was achieved with the introduction of solid- 
phase peptide synthesis (SPPS) with most peptides nowadays synthesised by this 
approach. It was first introduced and applied by Merrifield for the synthesis of a 
tetrapeptide (H-Leu–Ala–Gly–Val-OH) on a solid support.134 
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Figure 4.1. Structures of some macrocyclic peptides used as drugs. 
 
Specifically, Merrifield anchored an N-protected valine (Cbz-Val-OH) to a polymeric 
support (chloromethylated nitropolystyrene) via an SN2 reaction. After washing away 
the excess of reagents and by-products formed from the polymer-bonded amino 
acid, the protecting group on the N-terminus (Nα) of the Val was removed via HBr in 
AcOH and coupled via amidation reaction to the carboxylic acid of a second N-
protected amino acid, glycine (Cbz-Gly-OH). Re-iterating the cycle of wash, 
deprotection (HBr/AcOH) and coupling steps (DCCI), Merrifield successfully 
synthesised the tetrapeptide that could be released from the polymeric support by 
treatment with sodium hydroxide (Figure 4.2).  
The strategy was enormously successful due to the ease of the procedure and the 
simplicity of the purification steps, overcoming many of the technical difficulties 
associated with the solubility and the purification of synthesising peptides in solution 
that resulted in complex reaction mixtures and poor yields.135 
In the last years, SPPS had been extensively improved with the development of new 
solid supports, linkers and optimised reaction conditions and now it is routinely 
applied for the synthesis of complex organic molecules. 
One of the crucial steps in SPPS is the choice of the correct protecting group (PG) 
to mask functionalities on the amino acid backbone and side chain. A good 
protecting group should be easy to install, stable towards a broad range of reaction 
conditions, and its removal should require selective and mild reaction conditions in 





Figure 4.2. Representation of Merrifield’s solid-phase synthesis strategy conducted on a 
polymeric support (resin). The strategy starts with the covalent attachment of the first amino 
acid (protected at the N
α
-amino group) to the resin, followed by washing steps and 
deprotection of the protecting group (PG). The resin is then washed and the peptide 
sequence is elongated by adding stepwise each amino acid and repeating the 
coupling/deprotection/washing steps until the entire sequence is built. Once the peptide is 
formed, it can be cleaved from the polymeric support by saponification of the ester bond. The 
vital steps of mass action/reaction monitoring/ repeat couplings all ensure high quality 
product/peptides. 
 
In SPPS, today the two most widely used approaches are the tert-butyloxycarbonyl 
(Boc)/benzyl (Bn) and the 9-fluorenylmethoxycarbonyl (Fmoc)/tert-butyl (tBu) 
strategy. Both these strategies use “temporary” and “permanent” protecting groups 




The “temporary” group is usually installed on the Nα amino group and it is relatively 
easy to remove, while the “permanent” group’s cleavage typically needs stronger 
reaction conditions thus, its removal occurs at the end of the synthesis.  
 
Figure 4.3. Representation of the high/low acid and acid/base strategies in SPPS in the so-




In the Boc/Bn route, the benzyl (e.g. benzyl esters or benzyloxycarbonyl (Cbz)137) 
“permanent groups” are removed at the end by anhydrous HF or 
trifluoromethanesulfonic acid (TfOH) (Scheme 4.1). 138, 139 
 
 




The Boc140 group is used for the temporary protection of the Nα-amino functionality 
and removed at each step by treatment with acid (30–50% trifluoroacetic acid (TFA) 
in CH2Cl2). It is typically removed using TFA (2550%) in CH2Cl2 (Scheme 4.2), but 
HCl/dioxane or TsOH are equally capable. Boc shows high stability under basic and 
nucleophilic conditions, as well as catalytic hydrogenation. However, due to the 
acidic conditions used for its removal, it is not suitable when other acid sensitive 
protecting groups or acid labile linkers are present. The strong and hazardous acidic 
conditions used in the Boc/Bn route are not ideal, but do (due to the resin swelling 
with TFA at each step) give the best purity for long peptides. 
 




The Fmoc/tBu strategy was firstly introduced by Atherton and Sheppard, seeking an 
alternative strategy that could avoid the use of acid.142-144 Therefore they proposed 
the combination of a “permanent” acid-sensitive protecting group and a temporary 
PG which could be removed under mild basic conditions. In this strategy, the Nα-
amino function is temporarily masked using the Fmoc that can be cleaved by mild 
base treatment (20% piperidine in DMF). The tBu group is resistant to these basic 
conditions, and their removal occurs in the final stage using a strong acid (i.e. TFA). 
This class of protecting groups includes Boc, tBu ethers and esters and acid labile 
protecting groups, such as trityl (Trt). 
Fmoc145 represents one of the most popular protecting group in solid phase 
synthesis and a large number of Fmoc-protected building blocks are currently 
commercially available. Fmoc is efficiently removed under basic conditions and it is 




is the hydrophobicity of most of Fmoc-protected peptides that can result in low 
solubility in common solvents used in SPPS.  
 
 
Scheme 4.3. Deprotection mechanism of the Fmoc group by piperidine. 
 
The milder conditions used in Fmoc/tBu strategy are often preferred over the Boc/Bn 
route, but these conditions can be still incompatible with the synthesis of base 
sensitive peptides and milder and more selective protecting groups are often 
needed.146, 147  
 
4.2 Side-chain protecting groups for amines 
 
Usually, the elongation of a peptide chain by solid-phase synthesis is carried at the 
amino terminus, and therefore amine protecting groups are extremely important. 
However, sidechain amines are also strategically important and call for another set 
of protection strategies, to allow, for example peptide cyclisation. Selected examples 
are the 4-methyltrityl (Mtt), allyloxycarbonyl (Alloc) and the 1-(4,4-dimethyl-2,6-
dioxocyclohexylidene)ethyl (Dde) protecting groups (Figure 4.4).  
 
Figure 4.4. Protecting groups often used for lysine side chain temporary protection. 
 
The Mtt group is an electron-rich trityl derivative, initially introduced for the protection 
of asparagine and glutamine,148 however, it has been applied to the side-chain 




peptides.149 The Mtt is more acid-labile than the trityl group and its deprotection 
follows the same mechanism (Scheme 4.4),150 although less acidic conditions are 
required (typically TFA (1%) in CH2Cl2). These acidic conditions make this group 
compatible and orthogonal to many TFA-labile linkers and protecting groups. The 
lability can also be tuned by altering the substituent on the aryl group (R1 and R2). 
 
Scheme 4.4. Deprotection mechanism for trityl derivatives under acidic conditions. 
 
Some of the most used orthogonal protecting groups for side chain amines are the 
allyloxycarbonyl (Alloc)151 and 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde) 
groups (Figure 4.4).152  
Alloc is a popular protecting group for the synthesis of cyclic and branched peptides, 
and is stable under the acidic and basic conditions, which are typically used to 
remove other amine protecting groups such as Fmoc and Boc. Alloc can be 
removed upon treatment with palladium(0) in the presence of a scavenger (such as 
Me3NHBH3 or triisopropylsilane (TIPS))
153 that prevents the re-allylation of the free 
amine (Scheme 4.5).154-156 However, inert reaction conditions (nitrogen or argon 
atmosphere) are required to prevent oxidation and deactivation of the Pd-catalyst.157  
 
Scheme 4.5. Palladium-catalysed deprotection of Alloc group with and without a 
scavenger.
153
 The palladium-catalysed transfer of the allyl group from Alloc to a nucleophile 
(scavenger) results in the formation of the free amine, when the deprotection is performed 
with scavenger. A side reaction takes place, with the formation of allylamines without a 





Dde is another protecting group widely used for the protection of side-chain 
amines.158 It can be removed via hydrazinolysis (typically 2–5% NH2NH2 in DMF)
159 
(Scheme 4.6). However, these conditions also result in cleavage of the Fmoc and 
reaction (reduction) of Alloc groups.160, 161 In addition, in the presence of free primary 
amines,  the Dde group can undergo intra- and intermolecular N-migration.162  
Bradley160 developed new deprotection conditions for the selective removal of the 
Dde group in presence of Fmoc using a mixture of NH2OH·HCl/imidazole. 
 
 
Scheme 4.6. Deprotection mechanism of Dde with hydrazine. 
 
Bycroft extensively studied the stability of several Dde derivatives upon treatment 
with 20% piperidine in DMF and they showed that elongation/branching of the alkyl 
side chain on Dde improves its migration stability. Following these observations they 
introduced an improved version of Dde: the 1-(4,4-dimethyl-2,6-dioxocyclohex-1-
ylidene)-isovaleryl (ivDde) (Figure 4.5).163, 164 This Dde derivative can be cleaved by 
hydrazinolysis (2% NH2NH2 in DMF), moreover, due to steric hindrance it is also 
less prone to undergo N-migration. 
 





 4.3 Aims: the need for new orthogonal protecting groups 
 
Tuning and choosing the right set of orthogonal protecting groups that allow the 
synthesis of challenging complex targets, such as cyclic and branched peptides, is 
non trivial.157 
As discussed in the previous section, an array of orthogonal protecting groups for 
the lysine side-chain is already available, with Alloc and Dde being the most widely 
used. However, these two protecting groups still have limitations: the cleavage of 
Alloc group requires the use of palladium salts which potentially complicate the 
purification of peptides, especially for those used for biological applications while the 
method is best described as fickle. The reaction conditions used for the Dde 
removal are not fully orthogonal with Fmoc and Alloc groups and furthermore the 
Dde group does undergo N-migration.  
Therefore, to facilitate the synthesis of the more complex and sensitive targets, the 
design and the investigation of new orthogonal protecting groups that could be 
simply removed using mild conditions is desirable. 
The work in this chapter was focussed on an investigation of an alternative 
protecting group for the lysine side-chain which could be removed under mild and 
selective conditions. In particular, attention was directed to the design of a tetrazine-
labile protecting group for the synthesis of cyclic peptides via solid-phase synthesis.  
 
4.4 Vinyl Ether Benzyloxycarbonyl (VeZ): a tetrazine-labile 
protecting group  
 
Inverse-electron-demand Diels–Alder reactions (IEDDA) have been successfully 
used for the decaging of amino-functionalised cargos, for example in the effective 
release of the amino group of an anticancer drug (DOX) protected with a tetrazine-
labile moiety.31 It was envisioned the potential of using the same strategy for the 
temporary protection of side-chain amino functionalities. Specifically, ε-NH2 of 
lysines could potentially be protected via a carbamate linker to a self-immolative 




was envisioned to trigger a cascade reaction starting with the IEDDA reaction with 
the vinyl ether and followed by spontaneous 1,6-elimination to release the amino 
group of the lysine. 
 
Figure 4.6. Design of a new tetrazine-labile protecting group and its proposed mechanism 
for the decaging of amino-functionalised targets triggered by a tetrazine. 
 
As discussed in previous chapters, the rate of the IEDDA reaction can be tuned by 
changing the substituents on the dienophile, with electron-donating group raising 
energy of the HOMOdienophile and therefore accelerating the reaction. For this reason, 
in order to study electronic effects on the reaction rate, three VeZ (vinyl ether 
benzyloxycarbonyl) protecting groups were synthesised, bearing none (90), one (91) 
or two methoxy (92) groups in the ortho positions to increase the electron density in 
the ring (Figure 4.7).  
 





Starting from the corresponding commercially aldehydes 93a–c, the vinyl moiety 
was installed via a copper-catalysed vinylation protocol with vinyl boronic anhydride 
as the vinylating reagent,165  which gave the vinyl ethers 94a–c in 75–92% yield. 
The aldehyde moieties were reduced with NaBH4 to the corresponding benzylic 
alcohols 95a–c using NaBH4 and subsequently converted into the carbonates 96a–c 
using 4-nitrophenyl chloroformate in 75–78% yield (Scheme 4.7). 
 
 
Scheme 4.7. Synthetic scheme for the synthesis of nitrophenol precursors 96a-c. 
 
The ε-amino groups of two Nα-protected lysines, Fmoc-Lys-OH 97 and Cbz-Lys-OH 
98, were functionalised with the VeZ groups. To avoid the undesired reaction 
between the carboxylic acid of the lysine and the carbonate derivatives 96a–c, the 
C-terminus of Fmoc-Lys-OH 97 and Cbz-Lys-OH 98 were temporary masked by 
silylation with N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA).166 The addition 
of the carbonate precursors 96a–c in the presence of pyridine and trimethylamine 




protected lysines 99a–d in high yields (80–89% for the Fmoc-Lys-OH and 39% for 
Cbz-Lys-OH, Scheme 4.8).  
 
Scheme 4.8. Protection of the ε-NH2 of Cbz-Lys-OH 97 and Fmoc-Lys-OH 98 with the three 
VeZ derivatives. 
 
With these model compounds in hand, various conditions were screened in order to 
validate the deprotection of the VeZ group by treatment with the commercially-
available 3,6-di-2-pyridyl-1,2,4,5-tetrazine 21. When compound 99b was treated 
with tetrazine 21 in DMF at different temperatures (Table 4.1, entry 1–3), no 
conversion to Fmoc-Lys-OH 97 or the phenolic intermediate was observed after 24 
hours even at 60 °C (Entry 3). As discussed in Chapter 2, water has a significant 
effect on the reaction rates of Diels–Alder reactions by promoting the hydrophobic–
hydrophobic interactions between the reactants during the cycloaddition step.24, 25, 85 
In this case, the deprotection of 99b was investigated in the presence of water 
(Table 4.1, entry 4–6). The IEDDA reaction was promoted when 10% water was 
added to DMF (v/v %), with 80% conversion obtained at 60 °C (Entry 6). However, 
HPLC and 1H NMR analyses of the reaction mixture showed that although the 
IEDDA had taken place (Figure 4.6, with the appearance of the peak of phenol 100 
at 5.05 ppm), it was not followed by “spontaneous” 1,6-elimination reaction and the 
corresponding phenol 100 was obtained. Indeed the phenol 100 was isolated by 




Table 4.1. Screening of reaction conditions for deprotection of 99b with tetrazine 21. 
 
Entry Solvent Temp. Time Conversion  100:97 Ratio 
1 DMF rt 24 h 0% – 
2 DMF 40 °C 24 h 0% – 
3 DMF 60 °C 24 h 0% – 
4 DMF/H2O (9:1) rt 18 h 2% 1:0 
5 DMF/H2O (9:1) 40 °C 18 h 58% 1:0 
6 DMF/H2O (9:1) 60 °C 18 h 80% 1:0 
 
The reactivity of the three VeZ derivatives 99a–c was compared by 1H NMR in 
DMF-d7/D2O (9:1) with 3-(trimethylsilyl)-1-propanesulfonic acid sodium salt added as 
internal standard (Figure 3.5). Conversion was calculated monitoring the decrease 
of the vinyl ether peaks (H1 and H2) compared to the standard. The introduction of 
an electron donating methoxy group in the ortho position to the vinyl ether 
(compound 99b) only slightly increased the conversion into the phenol 100 (59%  vs 
55% after 24 hours, respectively). Introduction of a second ortho-methoxy group 
(compound 99c) did not promote the reaction instead led to a lower conversion 
(34% after 24 hours), attributed to increased steric hindrance. Hence, the mono-





Figure 4.6. Reaction between 99b and tetrazine 21 monitored over 24 h by 
1
H NMR. The 
spectra are zoomed in the “VeZ region”, showing the resonances corresponding to the vinyl 
ether protons (H1 and H2). The integrals were compared with the internal standard (3-
(trimethylsilyl)-1-propanesulfonic acid sodium salt) in order to calculate conversion.  
 
In order to promote the 1,6-elimination reaction, different reaction conditions were 
then screened (Table 4.2). Increasing the water content up to 50% resulted in the 
formation of the phenol 13 and the desired deprotected lysine 97 in 1:1.4 ratio (Entry 
2). Recently, it has been reported that lowering the pH accelerates the rate of the 
IEDDA (protonation of the tetrazine, increasing its electron-deficiency) and would 
simultaneously, promote the 1,6-elimination step.21 Thus, the reaction was 
performed in citrate buffer (pH = 5) in DMF (Entry 3–6), with full deprotection of the 
lysine observed using 1:1 ratio of citrate buffer and DMF at 60 °C for 18 h (Entry 3). 
In order to achieve a more optimal reaction time better applicable to SPPS, the 





71% conversion and 1:10 ratio of 100 and 97 obtained at 60 °C after 4 hour (Entry 
8). 
 
Table 4.2. Screening of reaction conditions for VeZ deprotection.  
Entry Solvent Temp. Time Conversion
[b]
 100:97 Ratio 
1 DMF/H2O (75:25) 60 °C 18 h 92% 1:1 
2 DMF/H2O (50:50) 60 °C 18 h 100% 1:1.4 
3 DMF/buffer
[a]
 (50:50) 60 °C 18 h 100% 0:1 
4 DMF/buffer
[a]
 (50:50) 40 °C (µW) 2 h 33% 2:1 
5 DMF/buffer
[a]
 (50:50) 40 °C (µW) 4 h 43% 2:1 
6 DMF/buffer
[a]
 (50:50) 60 °C (µW) 1 h 48% 1:1 
7 DMF/buffer
[a]
 (50:50) 60 °C (µW) 2 h 58% 1:3 
8 DMF/buffer
[a]
 (50:50) 60 °C (µW) 4 h 71% 1:10 
[a]
Sodium citrate (100 mM, pH = 5).
 [b]
Calculated by HPLC using 1-naphthol as a standard.  
 
The optimised reaction conditions (DMF/sodium citrate buffer (pH = 5) (50:50), 
60 °C (µW)) were then applied on solid-phase (Scheme 4.9), and, since the reaction 
shows the best results in aqueous conditions, ChemMatrix (an amino-functionalised 
PEG-based resin (loading: 1 mmol/g)) was selected as a solid support due to its 
stability at moderate high temperature and its water-compatibility.167 Other solid 
supports were trialled, such as polystyrene resin (PS), but unfortunately poor yields 
and not reproducible results were obtained due to the poor swelling in aqueous 
conditions.168 In this study, in order to minimize any possible side reactions linked to 
the stability of the Fmoc group at high temperature, the Cbz derivative 99d was 
selected to validate the deprotection conditions of the VeZ group on solid-phase. 
The resin was functionalised with a Rink-amide linker and subsequently coupled 
with Cbz-Lys(VeZ)-OH 99d (DIC/oxyma in DMF). As discussed in previous 
chapters, tetrazines can suffer from low hydrolytic stability, and as discussed in 
Chapter 2, tetrazine 21 has a hydrolytic stability of 2.9 ± 0.1 days in DMSO/H2O 
(1:1) at 37 °C. Because of the aqueous conditions and the high temperatures 
required for VeZ deprotection, in order to maximise the cleavage of the VeZ group, 
the resin was treated three times with a fresh solution of tetrazine 21 at 60 °C (µW) 
for 1 hour. After washing the resin, Fmoc-Gly-OH was coupled to the ε-NH2 and the 




the dipeptide 101 purified by semi-prep HPLC in quantitative yield (purity > 99%), 
proving the selectivity and the suitability of the VeZ group for solid-phase synthesis. 
 
Scheme 4.9. Synthesis of a model dipeptide 101 as proof-of-concept for the selective 
tetrazine-mediated deprotection of VeZ on solid phase. ChemMatrix resin was functionalised 
with Rink linker and Fmoc group was removed. The free amino group of the Rink linker was 
then coupled to the previously synthesised Cbz-Lys(VeZ)-OH 99d using DIC and oxyma as 
coupling reagents. The VeZ group was then deprotected by treating the resin three times 
with a solution of tetrazine 21 in DMF/citric acid buffer (pH = 5) for 1 hour at 60 °C (µW). The 
ε-amino group was coupled with Fmoc-Gly-OH, via oxyma/DIC activation in DMF. Lastly, the 
dipeptide 101 was cleaved from the resin by treatment with TFA/H2O/TIS (95:2.5:2.5) and 
isolated and characterized by HPLC. 
 
Any reaction conditions used in SPPS should not result in epimerisation of the 
amino acids used. To evaluate if the conditions used to remove the VeZ group were 
promoting epimerisation, two diasteroisomeric peptides 102a and 102b were 
synthesised on solid-phase. Fmoc-Lys(VeZ)-OH 99b was coupled (using 
DIC/oxyma) to ChemMatrix resin bearing  a Rink-amide linker and, after removal of 
the Fmoc group (20% piperidine in DMF), either Fmoc-(L)Phe-OH 103a or Fmoc-
(D)Phe-OH 103b were coupled (Scheme 4.10). After removal of the Fmoc and 
subsequent acetylation of the N-terminus, the VeZ group was deprotected by 




group and cleavage from the resin gave the dipeptides 102a and 102b as single 
diasteroisomers, with HPLC analysis showing no evidence of epimerisation (Figure 
4.8). 
 
Scheme 4.10. Evaluation of possible epimerisation of the amino acids upon VeZ cleavage 
by synthesis of dipeptide 102a. The same synthethic route was applied for the synthesis of 








Figure 4.8. A) HPLC (ELS detection) of the crude mixture with the diasteroisomer 102b. B) 
HPLC (ELSD) of the co-injection of both of the crude mixtures of 102a and 102b, showing 
two distinctive peaks and demonstrating that the epimerization did not occur. 
 
The compatibility and the orthogonality of VeZ as a protecting group for typical 
Fmoc-based SPPS conditions was evaluated by performing stability studies on two 
different VeZ protected lysines 99b and 99d (bearing Fmoc or a Cbz protecting 
groups) (Table 4.3). Fmoc-Lys(VeZ)-OH 99b (9 mM) was subjected to standard 
carbodiimide-activated coupling conditions (24 mM oxyma and 24 mM DIC in DMF) 
and showed good stability at room temperature and 60 °C (Entry 1 and 2). Fmoc-
Lys(VeZ)-OH 99b was also compatible with cleavage conditions used to remove the 
Alloc group (Entry 3), i.e. Pd(PPh3)4 (0.02 mM) and phenylsilane (80 mM) in DMF. 
Also, no decomposition was observed when a mixture of NH2OH·HCl/imidazole in 
NMP/DMF was used, showing that VeZ group was compatible with Dde cleavage 
(Entry 4). Cbz-Lys(Vez)-OH 99d was used to prove stability under basic 
deprotection conditions with the VeZ group being stable in DMF solutions of NH2NH2 
and piperidine used to removed Dde and Fmoc, respectively (Entry 5 and 6). The 
VeZ group was not compatible to strongly acidic conditions (≥ 20% TFA), perhaps 
due to the hydrolysis of the carbamate moiety; however, it showed good 










Table 4.3. Compatibility of VeZ group under standard SPPS conditions. Fmoc-Lys(Vez)-OH 
99b was subjected to conditions routinely used in SPPS and the stability evaluated by HPLC 
(ELSD and λ = 280 nm) using 1-naphthol as an HPLC standard. Cbz-Lys(VeZ)-OH 99d was 
used for Entry 5 and 6. 
Entry Reagents       Temp. time Stability 
1 24 mM Oxyma, 24 mM DIC, DMF rt 3 h Stable 
2 24 mM Oxyma, 24 mM DIC, DMF 60 °C 20 min Stable 










5 2% NH2NH2 in DMF rt 3 h *Stable 
6 20% Piperidine in DMF rt 1 h *Stable 
7 TFA/TIS/H2O (95/2.5/2.5) rt 1 h Not Stable 
8 20% TFA in DCM rt 1 h 58% Decomposition 
9 2% TFA in DCM rt 3 h Stable 
10 20% HFIP in DCM  rt 3 h Stable 
    *Stability tested on compound 99d. 
 
The compatibility of other protecting groups, such as Alloc and S-trytil (Trt), with 
tetrazine treatment were evaluated by HPLC studies. Fmoc-Lys(Alloc)-OH (9 mM) 
(Table 4.4) was not stable upon treatment with tetrazine 21 (27 mM) at 60 °C (µW) 
for 4 hours.  The Trt group, showed good stability and no decomposition of Fmoc-
Cys(Trt)-OH was observed under the VeZ cleavage conditions (Table 4.4). Among 
all the protecting groups, Alloc is the only group that proved not to be stable upon 
treatment with tetrazine, acting as dienophile in the IEDDA reaction and therefore 









Table 4.4. Stability studies of other commonly used protecting groups in SPPS: Alloc and Trt 
group upon VeZ deprotection conditions. The stability of those groups was monitored by 
HPLC (ELDS and λ = 280 nm) using 1-naphthol as an HPLC standard. 
 




1 27 mM 50% buffer
[a]
/DMF 4 h Not Stable Stable 
2 – 50% buffer
[a]








Finally, the scope of the VeZ protecting group was shown by the synthesis of two 
biologically relevant cyclic peptides, an analogue of melanotan (MT-II) 103,169 a 
potent and non-selective agonist of the melanocortin receptor, and a small 
peptidomimetic of Bcl-2 Homology protein (the BAD BH3 domain) 104 (Figure 
4.9).170 The corresponding linear peptides were synthesised on a ChemMatrix resin 
functionalised with the Rink linker and the cyclisation step performed on solid-phase 







Figure 4.9. Structure of the target cyclic peptides MT-II 103 and BAD BH3 104. 
 
For the synthesis of 103, Fmoc-Lys(VeZ)-OH 99b was coupled to the Rink linker 
using DIC/oxyma. The linear peptide sequence was built using standard Fmoc-
protected amino acids and Fmoc-Asp(2-PhiPr)-OH as an orthogonal building block 
to allow on resin side chain to side chain cyclisation (Scheme 4.11). The 2-
phenylisopropyl group (2-PhiPr) on the aspartic acid residue was first selectively 
deprotected using 3% TFA in CH2Cl2, and the ε-amino group of the lysine was then 
decaged using the optimised VeZ cleavage conditions (3 × 1 h at 60 °C, µW). The 
two aforementioned deprotection steps led to the release of the carboxylic acid of 
the aspartic acid residue and the primary amino group on the lysine chain without 
affecting the other protecting groups present on the linear peptide. The cyclisation 
was carried out on the resin using PyBOP/HOBt/DIPEA in DMF as the coupling 
combination, followed by treatment with strongly acidic conditions (TFA/H2O/TIS, 
95:2.5:2.5) to deprotect the other side-chain protecting groups (Pbf, Boc and Trt), 
and cleavage of the cyclic peptide off the resin. The peptide 103 was subsequently 





Scheme 4.11. Synthesis of MT-II 103 on ChemMatrix resin. After the corresponding linear 
peptide was built, the protecting groups on the Asp and Lys residues were removed with the 
tetrazine cleavage being used. The cyclisation was performed on-resin using 
PyBOP/HOBt/DIPEA as coupling reagents. The cyclic peptide 103 was then cleaved off the 






Figure 4.10. A) HPLC (detection by ELSD) of the final product 103 after cleavage from the 
resin and semi-prep HPLC purification (purity > 99%). B) MALDI-TOF spectrum of MT-II 103.  
 
A similar strategy was used to synthesise the BAD BH3 based small cyclic peptide 
104 (Figure 4.11). The corresponding linear peptide was built on Rink-functionalised 
ChemMatrix resin, using Fmoc-Lys(VeZ)-OH and Fmoc-Asp(2-PhiPr)-OH as the 
orthogonal building blocks. Once the linear peptide was formed, the 2-PhiPr and 
VeZ protecting groups were removed as described above, followed by the on-resin 
cyclisation, and deprotection and cleavage off the resin. The cyclic peptide 104 was 






Figure 4.11. A) Synthesis of the small cyclic peptide BAD BH3 analogue 104. B) HPLC 
(detection by ELSD) of the final product 104 after purification (purity > 99%). C) MALDI-TOF 






4.5. Conclusions and future work 
 
In conclusions, a tetrazine-labile protecting group for amino functionalities has been 
developed. Three vinyl ether benzyloxycarbonyl (VeZ) protecting groups were 
synthesised and their reactivity was investigated. The VeZ group was designed to 
be efficiently cleaved upon treatment with tetrazine via a IEDDA followed by a 
subsequent 1,6-elimination reaction. The orthogonality of VeZ with other commonly 
used protecting groups, such as Boc, Fmoc, Dde, was evaluated and showed fully 
compatibility with Fmoc deprotection and standard coupling conditions. The VeZ 
group was also stable upon weak acid treatment, while it showed partial 
decomposition under strongly acidic conditions. The optimized reaction conditions 
were applied to the synthesis of two biologically relevant cyclic peptides (MT-II and 
BAD BH3 analogue) via side-chain to side-chain cyclization performed on-resin. The 
VeZ group provides a good alternative to the Alloc and Dde groups and enriches the 







5.1 General information 
 
All chemicals were purchased from Acros Organics, Alfa Aesar, Fisher Scientific, 
FluoroChem or Sigma Aldrich and used as received. ChemMatrix resin was from 
Sigma Aldrich or Acros. Fmoc protected amino acids were purchased from GL 
Biochem (Shanghai) Ltd or NovaBiochem. Column chromatography purifications 
were carried out on silica gel 60 (230–400 mesh). Analytical TLC was carried out 
using commercially available silica gel F254 plates (Merck) and visualized with 254 
nm light. 1H and 13C NMR spectra were recorded on a Bruker AVA500 spectrometer 
(500 and 125 MHz, respectively) or on a Bruker AVA600 (600 and 150 MHz, 
respectively) at 298 K in deuterated solvents. The residual non-deuterated solvent 
peaks were used as a reference for 1H NMR experiments with CHCl3 (δH = 7.26 
ppm), CHD2OD (δH = 3.31 ppm), CD3SOCHD2 (δH = 2.50 ppm), CHD2CN (δH = 1.94 
ppm), (CHD2)(CD3)NCOD (δH = 2.75 ppm or 2.92 ppm) and HDO (δH = 4.79 ppm). 
The deuterated solvent signals were used as a reference for 13C NMR experiments 
with CDCl3 (δC = 77.2 ppm), CD3OD (δC = 49.0 ppm), (CD3)2SO (δC = 39.5 ppm), 
CD3CN (δC = 1.3 ppm or 118.3 ppm) and (CD3)2NCOD (δC = 29.8 ppm, 34.9 ppm or 
163.2 ppm). IR spectra were recorded on a Bruker Tensor 27 Standard System FT-
IR spectrophotometer. Analytical HPLC was performed on an Agilent Technologies 
1100 modular HPLC system coupled to a multiwavelength and PL-ELSD-1000 
detector and equipped with a Phenomenex Kinetex® 5µm XB-C18 100 Å column 
(50 × 4.6 mm), with a flow rate of 1 mL/min, eluting with 95% water for 5 min, then to 
95% CH3CN over 10 min (both with 0.1% HCO2H). High Resolution MS were 
performed on a Bruker microTOF focus II mass spectrometer. Stability studies were 
carried out recording the fluorescence spectra on a BioTek HT Synergy multi-mode 
reader. Kinetic measurements involving a fluorescence readout were performed on 
a FluoroMax-3 Jobin Yvon Div using a quartz cuvette. Reactions under microwave 
irradiation were performed using a Biotage® Initiator™. Irradiation of the resin was 






5.2 Prodrug-Prodrug activation 
 
5.2.1 Synthesis of key compounds 
Synthesis of 3-(methylthio)-6-(3-nitrophenyl)pyridazine 24 
 
 
Under an argon atmosphere, 3-chloro-6-(methylthio)pyridazine 34 (150 mg, 0.93 
mmol) and 3-nitrophenylboronic acid (151 mg, 0.90 mmol) were dissolved in 
dioxane/H2O (2:1, 2 mL). Pd(dppf)Cl2 (21 mg, 0.029 mmol) and potassium acetate 
(6 mg, 0.061 mmol) in dioxane/H2O (2:1, 1 mL) were added under argon to give a 
suspension. The mixture was heated under microwave irradiation at 80 °C for 2 h. 
The reaction was cooled to room temperature, and the mixture was filtered through 
a celite pad and then extracted with CH2Cl2 (20 mL). The organic layer was washed 
with H2O (5 mL) and brine (5 mL). The organic layer was dried over Na2SO4 and the 
solvent was removed under reduced pressure. The crude residue was purified by 
flash column chromatography (7:3, hexane/EtOAc) to give the pyridazine 24 as a 
pale yellow powder (111 mg, 50%).  
 
Rf 0.42 (hexane/EtOAc, 7:3). 
 
1H NMR (500 MHz, CD3OD): δ/ppm 8.95 (t, J = 2.0 Hz, 1H), 8.45 (ddd, J = 7.8,  1.8, 
1.0 Hz, 1H), 8.37 (ddd, J = 8.2,  2.3, 1.0, 1H), 8.06 (d, J = 9.1 Hz, 1H), 7.71 (t, J = 
8.2 Hz, 1H), 7.50 (d, J = 9.1 Hz, 1H), 2.74 (s, 3H). 
 
13C18 NMR (125 MHz, CD3OD): δ/ppm 164.9, 155.6, 150.4, 139.1, 133.6, 131.5, 
127.9, 125.5, 125.4, 122.5, 13.4. 
IR (solid, cm-1): 2926, 1519, 1396, 1347, 1160.  
HRMS (EI) for C11H9N3O2






Synthesis of 3-(methylthio)-6-(3-nitrophenyl)-1,2,4,5-tetrazine 25 
 
Thiocarbydaziunium salt 30 (407 mg, 1.6 mmol) was stirred with anhydrous pyridine 
(100 µL, 1.3 mmol) in anhydrous DMF (2 mL) at room temperature. After 5 minutes, 
the imidoester 31 (250 mg, 1.1 mmol) was added to the solution and the reaction 
mixture was stirred for 2 h at room temperature. The solvent was removed under 
reduced pressure and the crude mixture dissolved in CH2Cl2 (20 mL) and washed 
with H2O (2 × 20 mL) and brine (2 × 20 mL). The organic layer was dried over 
Na2SO4, filtered and concentrated under reduced pressure. The residue was 
dissolved in CH2Cl2 (10 mL) and amyl nitrite (267 µL, 0.87 mmol) was added 
dropwise. The solution was stirred at room temperature for 1 h. The solvent was 
removed under reduced pressure and the product purified by flash column 
chromatography (7:3, hexane/EtOAc) to give 25 as a red powder (25 mg, 9%). 
 
Rf 0.56 (hexane/EtOAc, 7:3).  
 
1H NMR (500 MHz, CD3CN): δ/ppm 9.20 (t, J = 1.8 Hz, 1H), 8.84 (ddd, J = 7.8, 1.7, 
1.0 Hz, 1H), 8.46 (ddd, J = 8.2, 2.3, 1.0, 1H), 7.87 (t, J = 7.8 Hz, 1H), 2.81 (s, 3H).  
 
13C{H} NMR (125 MHz, CD3CN): δ/ppm 177.3, 162.0, 150.1, 134.9, 133.9, 131.8, 
127.4, 122.7, 13.8.  
 
IR (solid, cm-1): 2927, 1519, 1396, 1347, 1161.  
 
HRMS (ESI) for C9H8O2N5









Synthesis of vinyl-O-camptothecin 26 
 
 
Under an argon atmosphere, [Ir(cod)Cl]2 (9.6 mg, 0.014 mmol) was stirred with 
Na2CO3 (91 mg, 0.86 mmol) in dry dioxane (0.5 mL) for 5 min. A solution of 
camptothecin (50 mg, 0.14 mmol) in dry dioxane (3 mL) was added to the reaction 
mixture under argon. Vinyl acetate (26 µL, 0.29 mmol) was added to the reaction 
mixture and it was stirred for 4 h at 100 °C under argon. The mixture was allowed to 
cool to room temperature and the solvent was removed under reduced pressure. 
The crude product was dissolved in CH3OH resulting in a fine suspension that was 
filtered prior to purification by preparative HPLC (45 min, gradient: 40 % CH3CN to 
60 % over 10 min, 80 % to 95 % over 25 min, 95 % for 5 min, 350 nm) to give 26 as 
a pale yellow powder (1 mg, 2%).  
 
Rf 0.27 (CH2Cl2/CH3OH, 98:2). 
 
1H NMR (500 MHz, CDCl3): δ/ppm 8.41 (s, 1H), 8.25 (d, J = 8.3 Hz, 1H), 7.94 (d, J = 
8.1 Hz, 1H), 7.85 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.68  (ddd, J = 9.5, 7.7, 0.8 Hz, 1H), 
7.42 (s, 1H), 6.18 (dd, J = 13.8, 6.5 Hz, 1H), 5.71 (d, J = 16.9 Hz, 2H), 5.36 – 5.28 
(m, 3H), 4.57 (dd, J = 13.9, 2.1 Hz, 1H), 4.25 (dd, J = 6.5, 2.1 Hz, 1H), 2.19 – 2.07 
(m, 2H), 1.05 (t, J = 7.5 Hz, 3H). 
 
13C{H} NMR (126 MHz, CDCl3): δ/ppm 168.6, 167.3, 152.5, 149.2, 147.5, 147.4, 
146.5, 131.3, 130.9, 130.0, 128.6, 128.3, 128.3, 128.3, 121.1, 98.2, 93.9, 78.8, 66.5, 
50.2, 32.5, 7.9. 
 
 IR (solid, cm-1): 2921, 2852, 1749. 1661. 
 
HRMS (ESI) for C22H19N2O4 [M+H]






Synthesis of thiocarbydaziunium iodide salt 30 
 
 
Following a literature procedure,93 a solution of thiocarbohydrazide 28 (2.0 g, 19 
mmol) in EtOH (8 mL) was heated to reflux and then a solution of methyl iodide (1.3 
mL, 21 mmol) in EtOH (8 mL) added dropwise. The reaction mixture was stirred for 
4 h, until a white precipitate formed. The reaction mixture was cooled to room 
temperature, the precipitate was collected by filtration and washed with EtOH (3 × 
10 mL) to give the product 30 as a white powder (3.6 g, 77%). 
1H NMR (500 MHz, D2O): δ/ppm 2.52 (s, 3H).  
13C{H} NMR (126 MHz, DMSO-d6): δ/ppm 170.6, 12.4.  
HRMS (ESI) for C2H9N4S [M
+]: calcd. 121.0542; found 121.0543. 
Data in agreement with those previously reported.93 
 
Synthesis of ethyl 3-nitrobenzimidate chloride salt 31 
 
To a solution of 3-nitrobenzonitrile 28 (1.2 g, 8.1 mmol) in dry EtOH (5 mL) at 0 °C, 
4N HCl in dioxane (10 mL) was added dropwise and the reaction mixture was stirred 
for 1 h at 0 °C. The solution was then warmed to room temperature and stirred 
overnight. The solvent was removed under reduced pressure, and the imidoester 31 
was isolated by precipitation in THF as a white powder (1.2 g, 65%).  
 
1H NMR (500 MHz, DMF-d7): δ/ppm 8.74 (ddd, J = 2.2, 1.6, 0.4 Hz, 1 H), 8.58 (ddd, 
J = 8.3, 2.4, 1.1 Hz, 1 H), 8.45 (ddd, J = 7.8, 1.6, 1.1 Hz, 1 H), 7.96 (t, J = 8.0 Hz, 1 




13C{H}  NMR (126 MHz, DMF-d7): δ/ppm 164.8, 148.4, 135.5, 132.1, 131.1, 128.0, 
62.3, 14.0. 
 
IR (solid, cm-1): 3006, 2813, 1635, 1617, 1532, 1348, 1102. 
 
HRMS (ESI) for C9H11O3N2 [M]
+ : calcd.: 195.0764; found: 195.0757. 
 
 
Synthesis of 3-chloro-6-(methylthio)pyridazine 34 
 
 
Triethylamine (705 µL, 5.1 mmol) was added dropwise to a solution of 3,6-
dichloropyridazine 33 (250 mg, 1.7 mmol) in dry DMF (5 mL). Sodium thiomethoxide 
(142 mg, 2.0 mmol) was slowly added dropwise to the reaction mixture over a period 
of 5 min. The resulting solution was stirred for 18 h at room temperature. After 
quenching the reaction mixture with cold CH3OH (1 mL), the solution was diluted in 
CH2Cl2 (15 mL) and washed with H2O (2 × 10 mL). The organic phase was washed 
with brine (2 × 10 mL) and dried over Na2SO4. The solvent was removed under 
reduced pressure and the crude oil was purified by flash column chromatography 
(7:3, hexane/EtOAc) to give 34 as a white powder (163 mg, 60%). 
 
Rf 0.39 (hexane/EtOAc, 7:3).  
 
1H NMR (500 MHz, CD3OD): δ/ppm 7.59 (d, J = 9.1 Hz, 1H), 7.54 (d, J = 9.1 Hz, 1H), 
2.66 (s, 3H).  
 
13C{H}  NMR (126 MHz, CD3OD): δ/ppm 164.7, 154.8, 130.0, 129.1, 13.4. 
 
 IR (solid, cm-1): 3063, 1592, 1393, 1161.  
 
HRMS (ESI) for C5H6N2





5.2.2 Determination of kinetics rate constants k2 
 
 
Second order rate constants (k2) were determined using pseudo-first order 
conditions and obtained by monitoring the decrease in absorption of tetrazine 25 (5 
mM, λabs = 520 nm) during treatment with an excess of 5-norbornen-2-ol 35 (12.5–
150 mM) (Figure 5.1) or ethylene glycol vinyl ether 36 (50–300 mM) in DMSO/H2O 
(10–50%) at 37 °C for 12 h (Figure 5.2). The decay in absorbance of tetrazine 25 
was plotted against time for 5 different concentrations of dienophile. The kobs values 
were determined by fitting to “one phase decay” equation (1) (non-linear regression) 
using Prism GraphPad Software and the values obtained from the slopes. Each 
experiment was repeated three times. Reaction rates k2 were determined by plotting 
kobs against the concentrations of vinyl ether 36 or norbornene 35, with k2 being the 
slope of the corresponding linear fit (see Figure 2.14 and 2.15, Chapter 2).  
 
                Y = [Y(0) – plateau] ×  e(–kobs × t) + plateau                                        (1) 
  
The water dependency was evaluated by plotting and fitting of the k2 values of the 
reaction between tetrazine 25 and vinyl ether 36 versus the water content, giving an 
exponential graph with calculation from equation (2) (R2 of 0.998, Figure 5.1):  
 
k2 = k2
0 (1+r)water content     (2) 
r = 0.0504 
k2
0 = 1.679 × 10-5 M-1 s
-1 
 
Figure 5.1. Rate constants k2 of the reaction between tetrazine 25 and the vinyl ether 36 





The rate constant for the tetrazine 25 with ethylene glycol vinyl ether 35 was 2.1 ± 
0.3 × 104 M1 s1 in DMSO/H2O (1:1).
33, 81, 171 
Extrapolation of the reaction rates constant to 100% water gave a reaction rate of 
2.3 × 103 M1 s1.24, 25, 172 
 
 
5.2.3 Stability studies  
 
5.2.3.1   Tetrazine half-life (t1/2) 
 
The half-lives (t1/2) of tetrazine 25 and tetrazine 21 were determined by measuring 
(in triplicate) the decrease in the absorbance (at λ = 540 nm) of tetrazine (5 mM) 
over time in PBS/DMSO (1:1) and in PBS/H2O (1:1) plotting the normalised natural 
logarithm of concentration (ln(ci /c0)) against time (Figure 5.2 and Figure 5.3). The 
half-life (t1/2) of tetrazine 25 and 21 were calculated using equation (3): 
 





















Stability in DMSO/H2O (1:1)
  
Figure 5.2. Plot of normalised natural logarithm of tetrazine 25 concentration (ci) against 

















Stability in DMSO/H2O (1:1)





Figure 5.3. Plot of normalised natural logarithm of tetrazine 21 concentration (ct) against 
time in DMSO/H2O (left) and DMSO/PBS (right). 
 
5.2.3.2     Stability in the presence of glutathione (GSH) 
 
The stability of tetrazine 25 in the presence of glutathione was determined by HPLC 
using 3,5-trimethoxybenzene as a HPLC standard (see Figure 2.17, Chapter 2). 
Tetrazine 25 (2 mM) was mixed with reduced glutathione (5 mM) in CH3CN/H2O 
(1:1) at 37 °C. Another reaction was performed without glutathione and used as a 
control. After 3 days, an aliquot (20 µL) was taken and diluted in CH3CN (100 µL) 
containing 0.1 % HCO2H. Samples were analysed by analytical HPLC (10 min, 





5.2.4 Prodrug activation studies by HPLC 
 
5.2.4.1     Reaction with biocompatible dienophile vinyl-O-nucleoside  
 
The reaction between tetrazine 25 and vinyl-O-nucleoside 37 was monitored by 
HPLC using stock solutions (100 mM in DMSO) of 25 and 37 diluted into 
CH3CN/H2O (1:1) to give final concentrations of 32 mM and 16 mM, respectively 
(see Figure 2.18, Chapter 2). The reaction was performed at 37 °C and aliquots (20 




0.1 % HCO2H. Samples were analysed by analytical HPLC (10 min, gradient: 5% 
CH3CN to 95 % in 6 min, 95 % for 3 min, 5 % for 1 min, 254 nm).  
 
 
5.2.4.2     Prodrug–Prodrug activation 
 
 
The release of the two active drugs 24 and CPT was monitored by HPLC using 
resorufin as HPLC standard (see Figure 2.21, Chapter 2). Stock solutions (100 mM, 
DMSO) of tetrazine 25 and vinyl-CPT 26 were diluted in CH3CN/CH3OH/H2O (4:5:1) 
to give final concentrations of 0.5 mM and 10 mM, respectively. Aliquots (20 µL) 
were taken, diluted in CH3CN containing 0.1 % HCO2H and analysed by analytical 
HPLC (10 min, gradient: 5% CH3CN to 95 % in 6 min, 95 % for 3 min, 5 % for 1 min, 
























5.3 Tetrazine-activated “turn-on” probe 
 
5.3.1  Synthesis of tetrazine probes 
 
Synthesis of tetrazine-BODIPY 64 
 
Compound 79 (99 mg, 0.49 mmol) and 2,4-dimethylpyrrole (102 µL, 0.99 mmol) 
were dissolved in anhydrous THF (10 mL) under Ar atm. TFA (10 µL) was added 
and the reaction mixture was stirred at room temperature for 18 h. The mixture was 
cooled to 0 °C and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 225 mg, 0.99 
mmol) in anhydrous THF (6 mL) was added dropwise, and mixture was stirred at 
room temperature for 5 h under an Ar atm. Triethylamine (1.5 mL, 10 mmol) was 
added under Ar at 0 °C and the reaction was stirred for additional 30 min. Then, 
BF3·OEt2 (1.8 mL, 15 mmol) was added dropwise at 0 °C and the mixture stirred at 
room temperature for 18 h. The solvent was removed in vacuo and the residue was 
dissolved in CH2Cl2 (30 mL) and washed with NH4Cl (2 × 20 mL) and brine (2 × 20 
mL). After evaporation, the crude product was purified by flash column 
chromatography (toluene/hexane, 4:1) to give tetrazine 64 as red crystals (79 mg, 
38%). 
1H NMR (500 MHz, CDCl3): δ/ppm 8.72 (ddd, J = 8.0, 1.8, 1.2 Hz, 1H), 8.59 (d, J = 
1.8 Hz, 1H), 7.75 (t, J = 7.8 Hz, 1H), 7.58 (ddd, J = 7.6, 1.8, 1.2 Hz, 1H), 6.00 (s, 
2H), 3.11 (s, 3H), 2.57 (s, 6H), 1.44 (s, 6H).  
13C{H} NMR (125 MHz, CDCl3): δ/ppm 167.8, 163.8, 156.2, 143.0, 140.3, 136.4, 
133.1, 132.4, 131.5, 130.3, 128.5, 127.8, 121.7, 21.4, 15.0. 14.8. 
HRMS (ESI) for C22H22
11BF2N6 [M+H]
+: calcd.: 419.1962; found: 419.1962.  








5-Bromo-2-pyridinecarbonitrile (50 mg, 0.273 mmol), 7-amino-4-methylcoumarin 
(57.4 mg, 0.328 mmol), K2CO3 (132 mg, 0.956 mmol), Pd(OAc)2 (1.23 mg, 0.005 
mmol) and BINAP (3.40 mg, 0.005 mmol) were mixed into a microwave vial and dry 
toluene (2 mL) was added. The vial was sealed, evacuated and flushed with 
nitrogen. The reaction mixture was heated at 180 °C in a microwave for 90 min. 
After cooling to room temperature, the solid was filtered off and washed with CH2Cl2 
(3 × 10 mL) and acetone (3 × 10 mL). The precipitate was collected was dried in a 
40 °C vacuum oven overnight to give the product 68 as a yellow solid (56 mg, 74%). 
Rf 0.75 (hexane/EtOAc, 3:7). 
1H NMR (500 MHz, DMSO-d6): δ/ppm 8.46 (d, J = 2.7 Hz, 1 H), 7.82 (d, J = 8.6 Hz, 
1 H), 7.73 – 7.63 (m, 2 H), 7.16 (dd, J = 8.6, 2.3 Hz, 1 H), 7.12 (d, J = 2.2 Hz, 1 H), 
6.19 (d, J = 1.4 Hz, 1 H), 2.39 (d, J = 1.2 Hz, 3 H).  
13C{H} NMR (126 MHz, DMSO-d6): δ/ppm 160.6, 155.0, 153.6, 143.2, 141.5, 130.3, 
127.0, 122.1, 121.9, 118.9, 115.3, 111.5, 110.0, 104.4, 18.5. 
 
LCMS (ESI) for C16H12N3O2 [M+H]










Synthesis of tetrazine-BODIPY 71 
 
Triethylamine (93 µL, 0.68 mmol) was dissolved in anhydrous DMF (3 mL) and 
degassed with the flow of N2 for 20 minutes. BODIPY-acetyline 82 (65 mg, 0.19 
mmol), tetrazine 81 (40 mg, 0.13 mmol), Pd(PPh3)2Cl2 (9.4 mg, 0.013 mmol) and 
CuI (2.5 mg, 0.013 mmol) were mixed and dissolved with degassed 
triethylamine/DMF solution. The mixture was further degassed with the flow of N2 for 
10 minutes and stirred for 24 hours at room temperature. The solvent was removed 
under reduced pressure and the residue purified by flash column chromatography 
(toluene) to give tetrazine 71 as a pink solid (40 mg, 57%). 
1H NMR (500 MHz, CDCl3): δ/ppm 8.62 (d, J = 8.7 Hz, 2H), 7.74 (dd, J = 16.6, 8.6 
Hz, 4H), 7.33 (d, J = 8.5 Hz, 1H), 6.00 (s, 2H), 3.12 (s, 3H), 2.57 (s, 6H), 1.45 (s, 
6H).  
13C{H} NMR (125 MHz, CDCl3): δ/ppm 167.3, 163.7, 155.9, 143.0, 140.6, 135.5, 
132.5, 132.4, 131.6, 131.2, 128.4, 127.9, 127.2, 123.6, 121.4, 91.7, 90.1, 21.2, 14.6.  
HRMS (ESI) for C30H25
11BF2N6 [M+H]
+: calcd.: 519.2275; found: 519.2312. 








Synthesis of benzonitrile BODIPY 72 
 
To 3-formylbenzonitrile (1.0 g, 7.6 mmol) and 2,4-dimethylpyrrole (1.7 mL, 17 mmol) 
in CH2Cl2 (80 mL) under a nitrogen atmosphere, TFA (10 µL) was added and the 
mixture was stirred at room temperature. After 30 minutes, a solution of DDQ (1.7 g, 
7.6 mmol) in CH2Cl2 (50 mL) was added followed by N,N-diisopropylethylamine (15 
mL, 89 mmol) and BF3·OEt2 (15.5 mL, ~45% BF3 content). The reaction was stirred 
overnight and then water (100 mL) was added and the aqueous phase was 
extracted with CH2Cl2 (3 × 100 mL). The combined organic extracts were dried with 
MgSO4 and the solvent evaporated in vacuo. The crude mixture was purified by 
flash column chromatography (toluene/hexane, 3:1) to give 72 (192 mg, 3%) as a 
red solid. 
 
1H NMR (500 MHz, DMSO-d6): δ/ppm 8.04 (m, 1H), 8.00 (m, 1H), 7.78 (m, 2H), 6.21 
(s, 2H), 2.46 (s, 6H), 1.33 (s, 6H). 
13C{H} NMR (500 MHz, DMSO-d6): δ/ppm 155.5, 144.5, 139.0, 139.2, 135.6, 133.2, 
132.1, 131.8, 130.6, 121.7, 118.1, 112.5, 30.6, 14.2.  
LCMS (ESI) for C20H19
11BF2N3 [M+H]
+: calcd.: 350.2; found: 350.2. 













Under a nitrogen atmosphere, to a solution of 3-(hydroxymethyl)benzonitrile 77 (500 
mg, 3.8 mmol) and InCl3 (85 mg, 0.38 mmol) in CH2Cl2 (10 mL), 2,4-dimethylpyrrole 
(850 µL, 7.8 mmol) was added and the reaction mixture was stirred overnight at 
room temperature. Then, KOH (280 mg, 5.0 mmol) was added and the reaction was 
stirred for additional 45 min. The reaction mixture was filtered and the solvent 
removed in vacuo. The product 75 was directly used for the next step without further 
purification. To a solution of 75 (1.24 g, 5.1 mmol) in CH2Cl2 (10 mL),  2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ, 928 mg, 5.1 mmol) was added and the 
reaction was stirred overnight at room temperature. The solvent was removed in 
vacuo and the crude product was purified by flash column chromatography 
(CH2Cl2/CH3OH, 9:1) to give the compound 76 (683 mg, 56%). 
 
1H NMR (500 MHz, DMSO-d6): δ/ppm 8.16 (dd, J = 7.6, 1.5 Hz, 1H), 7.92 (s, 1H), 
7.78 (t, J = 7.7 Hz, 1H), 7.71 (d, J = 7.9 Hz, 1H), 6.50 (s, 2H), 5.75 (d, J = 1.2 Hz, 
1H), 2.43 (s, 6H),1.63 (s, 6H). 
13C{H} NMR (125 MHz, DMSO-d6): δ/ppm 153.4, 142.9, 137.6, 136.0, 130.9, 130.8, 
121.2, 118.5, 116.7, 112.9, 55.4, 31.2, 14.4. 
LCMS (ESI) for C20H20N3 [M+H]











 3-(Hydroxymethyl)benzonitrile 77 (200 mg, 1.5 mmol), Ni(OTf)2 (268 mg, 0.75 
mmol), acetonitrile (3.9 mL, 75 mmol), and hydrazine monohydrate (727 µL, 75 
mmol) were mixed in a microwave vial and sealed. The reaction mixture was stirred 
for 48 h at 60 °C. After cooling to 0 °C, water (10 mL) was added and the mixture 
was extracted with CH2Cl2 (2 × 20 mL). The organic layers were combined, dried 
over Na2SO4, filtered and concentrated under reduced pressure. The residue was 
dissolved in anhydrous CH2Cl2 (5 mL), PhI(OAc)2 (725 mg, 2.3 mmol) was added, 
and the reaction mixture was stirred for 3 h. The solvent was evaporated in vacuo 
and the crude product was purified by flash column chromatography (hexane/EtOAc, 
7:3) to give the compound 78 as a pink solid (127 mg, 42%). 
1H NMR (500 MHz, CDCl3): δ/ppm 8.58 (s, 1H), 8.51 (d, J = 7.7 Hz, 1H), 7.65 (d, J = 
8.4 Hz, 1H), 7.59 (t, J = 7.7 Hz, 1H), 4.84 (s, 2H), 3.10 (s, 3H).  
13C{H} NMR (125 MHz, CDCl3): δ/ppm 167.5, 164.2, 142.3, 132.2, 131.2, 129.7, 
127.3, 126.4, 65.1, 21.3. 
HRMS (ESI) for C10H11ON4 [M+H]
+: calcd.: 203.0927; found: 203.0928. 














 Tetrazine benzylic alcohol 78 (127 mg, 0.62 mmol) and Dess–Martin periodinane 
(291 mg, 0.69 mmol) were dissolved in CH2Cl2 (10 mL) and the reaction mixture was 
stirred 2 h at room temperature. The mixture was filtered and the filtrate was 
concentrate in vacuo. The crude product was purified by flash column 
chromatography (hexane/EtOAc, 7:3) to give compound 79 as a pink solid (99 mg, 
80%). 
1H NMR (400 MHz, CDCl3): δ/ppm 10.18 (d, J = 0.6 Hz, 1H), 9.11 (t, J = 1.7, 1H), 
8.87 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H), 8.17–8.15 (m, 1H), 7.79 (t, J = 7.8, 1H), 3.14 (s, 
3H).  
13C{H} NMR (100 MHz, CDCl3): δ/ppm 191.5, 168.0, 163.5, 137.4, 133.4, 133.0, 
132.6, 130.1, 130.0, 21.4.  
HRMS (ESI) for C10H9ON4 [M+H]
+: calcd.: 201.0771; found: 201.0779. 
















Commercially available 4-iodobenzonitrile (100 mg, 0.44 mmol) was mixed with 
Ni(OTf)2 (78 mg, 0.22 mmol), acetonitrile (230 µL, 4.4 mmol) and hydrazine 
monohydrate (1.1 mL, 22 mmol) in a microwave vial and sealed. The reaction 
mixture was stirred for 24 hours at 60 °C. After cooling down to 0 °C, the mixture 
was diluted in water (5 mL) and a solution of NaNO2 (607 mg, 8.8 mmol) in water (5 
mL) was added followed by the dropwise addition of 1 M HCl until pH = 3 was 
reached (ATTENTION – formation of nitrous fumes at this stage!).  The mixture was 
extracted in EtOAc (2 × 30 mL). The organic layers were combined and dried over 
Na2SO4, filtered and concentrated under reduce pressure. The crude product was 
purified by flash column chromatography (toluene/hexane, 4:1) to give the 
compound 81 as a pink solid (127 mg, 42%). 
1H NMR (500 MHz, CDCl3): δ/ppm 8.32 (m, 2H), 7.95 (m, 2H), 3.10 (s, 3H). 
13C{H} NMR (125 MHz, CDCl3): δ/ppm 167.7, 163.9, 138.7, 131.5, 129.4, 100.3, 
77.4, 77.2, 76.9, 21.4. 
LCMS (ESI) for C9H8IN4 [M+H]
+: calcd.: 298.0; found: 298.0. 










5.3.2 Fluorescence studies 
 
Fluorescence measurements were carried out on a FluoroMax-3 fluorimeter (λex = 
488–490 nm) using a quartz cuvette. The purity of all compounds was verified by 
analytical HPLC before performing the reaction. The fluorescence measurements of 
tetrazine 71 and 64 were performed in triplicate before the addition of the dienophile 
(time zero). After addition of the polymer 83 (12 µM), the fluorescence emission was 
monitored until a plateau was reached (2 h). Fluorescence intensities were 
normalised and the turn-on ratios calculated from the peak of maximum emission 
intensity and to the emission of the tetrazine probes at time zero. (See Figure 3.17 
and 3.18, Chapter 3) 
 
 
Figure 5.4. Fluorescence spectra of (a) tetrazine 71 and (b) tetrazine 64 (both at 1 µM in 
PBS) before and after the addition of the polymer 83 (12 µM for 30 min at 37 °C). 
 
 
5.3.3 Stability studies 
 
Samples for fluorescence measurements were prepared from 10 mM stock solutions 
of the tetrazine probe in DMSO. The dyes were diluted to various concentrations in 
aqueous PBS serum-free media and cell culture media (with 10% FBS, v/v). The 
stability of tetrazine 71 (µM) or tetrazine 64 (1 µM) were determined by monitoring 
the change fluorescence intensity with multimode plate reader (λex = 465–505 nm, 
λem = 508–548 nm) using black 96-well plates. The fluorescence intensity readings 
were taken every 5 min at 37 °C and the experiment was performed in triplicates 




5.4 Tetrazine-labile protecting group for solid-phase synthesis 
 
5.4.1 Synthesis of VeZ protecting groups 
General protocol for the synthesis of compounds 94a–c 
 
 
Copper(II) acetate (580 mg, 3.2 mmol) was stirred at room temperature in 
anhydrous CH2Cl2 (20 mL) for 10 min. Vinylboronic anhydride (510 mg, 2.1 mmol), 
93a, 93b or 93c (3.2 mmol) and pyridine (2.6 mL, 32 mmol) were added, and the 
reaction was stirred for 24 hours with a CaCl2 drying tube. The reaction mixture was 
washed with 3 M aqueous ammonium acetate (2 × 40 mL), and the combined 
aqueous layers were extracted with EtOAc (3 × 40 mL). The organic layers were 
combined, washed with 2 M HCl (2 × 40 mL), brine (2 × 40 mL), dried over Na2SO4, 
and concentrated in vacuo. The resulting crude was purified by silica column 
















Synthesis of 4-vinyloxybenzaldehyde (94a)  
 
Colourless oil. Yield: 90% (427 mg). 
Rf 0.69 (7:3, hexane/EtOAc). 
1H NMR (500 MHz, CDCl3): δ/ppm 9.95 (s, 1H), 7.90 (d, J = 8.7 Hz, 2H), 7.14 (d, J = 
8.7 Hz, 2H), 6.72 (dd, J = 13.6, 6.0 Hz, 1H), 4.97 (dd, J = 13.6, 1.8 Hz, 1H), 4.66 
(dd, J = 6.0, 1.9 Hz, 1H).  
13C{H} NMR (125 MHz, CDCl3): δ/ppm 190.8, 161.6, 146.3, 132.0, 131.6, 116.7, 
98.2.  
HRMS (ESI) for C9H9O2 [M+H]
+ : calcd. 149.0616; found 149.0597. 
Data in agreement with the literature.174 
 
 
Synthesis of 4-vinyloxy-3-methoxybenzaldehyde (94b)  
 
Yellowish oil. Yield 92% (525 mg). 
Rf 0.67 (7:3, hexane/EtOAc).  
1H NMR (500 MHz, CDCl3): δ/ppm 9.89 (s, 1H), 7.47 (d, J = 1.8 Hz, 1H), 7.44 (dd, J 
= 8.1, 1.9 Hz, 1H), 7.10 (d, J = 8.1 Hz, 1H), 6.64 (dd, J = 13.7, 6.0 Hz, 1H), 4.94 (dd, 




13C{H} NMR (125 MHz, CDCl3): δ/ppm 191.1, 151.3, 150.4, 147.2, 132.4, 125.9, 
116.3, 110.5, 97.9, 56.3.  
HRMS (ESI) for C10H11O3 [M+H]
+ : calcd. 179.0703; found 179.0694. 
Data in agreement with the literature.175 
 
Synthesis of 4-vinyloxy-3,5-dimethoxybenzaldehyde (94c)  
 
White powder. Yield: 75% (500 mg). 
Rf 0.60 (7:3, hexane/EtOAc). 
1H NMR (500 MHz, CDCl3): δ/ppm 9.90 (s, 1H), 7.16 (s, 2H), 6.59 (dd, J = 13.8, 6.2 
Hz, 1H), 4.40 (dd, J = 13.8, 2.4 Hz, 1H), 4.24 (dd, J = 6.2, 2.4 Hz, 1H), 3.92 (s, 6H). 
13C{H} NMR (125 MHz, CDCl3): δ/ppm 191.1, 153.4, 150.6, 138.6, 133.2, 106.8, 
90.7, 56.6.  
HRMS (ESI) for C11H13O4 [M+H]
+ : calcd. 209.0808; found 209.0820. 
IR (solid, cm-1): 2846, 1685, 1641, 1586, 1497, 1457, 1387, 1326, 1231, 1117, 948, 











General protocol for the synthesis of compounds 95a–c 
 
 
NaBH4 (280 mg, 7.5 mmol) was added dropwise at 0
 °C to a stirred solution of 
aldehyde 94a, 94b or 94c (2.5 mmol) in absolute ethanol (5 mL). The reaction 
mixture was stirred for 1 hour at room temperature. The reaction was quenched with 
water (3 mL) at 0 °C and diluted with CH2Cl2 (20 mL). The mixture was separated 
and extracted with CH2Cl2 (3 × 20 mL) and the combined organic layers dried over 
Na2SO4, and concentrated in vacuo to give the products 95a–c, which were used 
without further purification. 




Colourless oil. Yield: 96% (360 mg). 
Rf 0.47 (6:4, hexane/EtOAc). 
1H NMR (500 MHz, CDCl3): δ/ppm 7.35 (d, J = 8.6 Hz, 2H), 7.02 (d, J = 8.6 Hz, 2H), 
6.66 (dd, J = 13.7, 6.1 Hz, 1H), 4.79 (dd, J = 13.7, 1.7 Hz, 1H), 4.67 (s, 2H), 4.46 
(dd, J = 6.1, 1.7 Hz, 1H).  
13C{H} NMR (125 MHz, CDCl3): δ/ppm 156.3, 148.2, 135.7, 128.6, 117.2, 95.2, 64.9. 
HRMS (ESI) for C9H11O2 [M+H]
+: calcd. 151.0754; found 151.0727. 




Synthesis of [4-(ethenyloxy)-3-methoxyphenyl]methanol (95b) 
 
 
White powder. Yield: 91% (409 mg). 
Rf 0.38 (1:1, hexane/EtOAc).  
1H NMR (500 MHz, CDCl3): δ/ppm 6.99 (d, J = 2.0 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 
6.89 (dd, J = 13.8, 6.1 Hz, 1H), 6.59 (dd, J = 13.8, 6.1 Hz, 1H), 4.69 (dd, J = 13.8, 
1.9 Hz, 1H), 4.66 (d, J = 5.8 Hz, 2H), 4.39 (dd, J = 6.1, 1.9 Hz, 1H), 3.89 (s, 3H), 
1.67 (t, J = 5.9 Hz, 1H).  
13C{H} NMR (125 MHz, CDCl3): δ/ppm 150.4, 149.4, 146.2, 137.2, 119.4, 118.6, 
111.5, 94.2, 65.3, 56.1.  
HRMS (ESI) for C10H13O3 [M+H]
+ calcd. 181.0859; found 181.0867. 
IR (solid, cm-1): 3334, 2938, 2873, 1639, 1507, 1463, 1417, 1309, 1263, 1221, 1150, 






















Yellowish oil. Yield: 92% (483 mg).  
Rf 0.32 (1:1, hexane/EtOAc). 
1H NMR (500 MHz, CDCl3): δ/ppm 6.64 (s, 2H), 6.57 (dd, J = 13.9, 6.3 Hz, 1H), 4.66 
(d, J = 4.8 Hz, 2H), 4.36 (dd, J = 13.9, 2.2 Hz, 1H), 4.17 (dd, J = 6.3, 2.2 Hz, 1H), 
3.85 (s, 6H), 1.79 (t, J = 5.6 Hz, 1H).  
13C{H} NMR (125 MHz, CDCl3): δ/ppm 153.1, 151.4, 138.2, 132.5, 104.0, 89.6, 65.5, 
56.4. 
HRMS (ESI) for C11H15O4 [M+H]
+ calcd. 211.0965; found 211.0955. 



















To a solution of 95a, 95b or 95c (2.7 mmol) in anhydrous CH2Cl2 (10 mL), 4-
nitrophenyl chloroformate (840 mg, 4.2 mmol) in anhydrous CH2Cl2 (3 mL) and 
pyridine (400 µL, 5.4 mmol) were added at 0 °C under a N2 atm. The reaction was 
stirred for 3 hours at room temperature. The reaction mixture was washed with 2 M 
HCl (2 × 5 mL) and saturated aqueous NaHCO3 (2 × 5 mL). The organic layer was 
dried over Na2SO4 and concentrated in vacuo. The resulting crude was purified by 
silica column chromatography (9:1, hexane/EtOAc) to afford the products 96a–c as 

















White powder Yield: 72% (612 mg). 
Rf  0.45 (7:3, hexane/EtOAc). 
1H NMR (500 MHz, CDCl3): δ/ppm 8.27 (d, J = 9.1 Hz, 2H), 7.42 (d, J = 8.6 Hz, 2H), 
7.38 (d, J = 9.1 Hz, 2H), 7.04 (d, J = 8.5 Hz, 2H), 6.65 (dd, J = 13.7, 6.0 Hz, 1H), 
5.26 (s, 2H), 4.82 (dd, J = 13.7, 1.7 Hz, 1H), 4.50 (dd, J = 6.1, 1.7 Hz, 1H).  
13C{H} NMR (125 MHz, CDCl3): δ/ppm 157.6, 155.7, 152.6, 147.7, 145.6, 130.8, 
129.0, 125.4, 121.9, 117.3, 96.2, 70.8.  
HRMS (ESI) for C16H13NO6 [M+Na]
+: calcd. 338.0635; found 338.0631. 















Synthesis of [4-(Ethenyloxy)-3-methoxyphenyl]methyl 4-nitrophenyl carbonate 
(96b) 
 
White powder. Yield: 75% (701 mg).  
Rf 0.43 (7:3, hexane/EtOAc). 
1H NMR (500 MHz, CDCl3): δ/ppm 8.28 (d, J = 9.3 Hz, 2H), 7.38 (d, J = 9.2 Hz, 2H), 
7.04–7.00 (m, 3H), 6.60 (dd, J = 13.7, 6.1 Hz, 1H), 5.25 (s, 2H), 4.76 (dd, J = 13.7, 
1.9 Hz, 1H), 4.45 (dd, J = 6.1, 1.9 Hz, 1H), 3.91 (s, 3H).  
13C{H} NMR (125 MHz, CDCl3): δ/ppm 155.6, 152.6, 150.4, 148.8, 146.5, 145.6, 
130.1, 125.5, 121.9, 121.8, 118.3, 113.2, 95.2, 71.0, 56.3. 
HRMS (ESI) for C17H15NO7 [M+Na]
+: calcd. 368.0741; found 368.0746. 





















White powder. Yield: 78% (792 mg).  
Rf 0.48 (7:3, hexane/EtOAc).
  
1H NMR (600 MHz, CDCl3): δ/ppm 8.29 (d, J = 9.2 Hz, 2H), 7.40 (d, J = 9.2 Hz, 2H), 
6.70 (s, 2H), 6.57 (dd, J = 13.9, 6.3 Hz, 1H), 5.25 (s, 2H), 4.38 (dd, J = 13.9, 2.2 Hz, 
1H), 4.20 (dd, J = 6.3, 2.2 Hz, 1H), 3.88 (s, 6H).  
13C{H} NMR (150 MHz, CDCl3): δ/ppm 155.6, 153.1, 152.6, 151.2, 145.6, 133.8, 
131.3, 125.5, 121.9, 106.1, 90.0, 71.2, 56.6.  
HRMS (ESI) for C18H18NO8 [M+H]
+: calcd. 376.1027; found 376.1010. 


















α-Amino protected lysine (Fmoc-Lys-OH or Cbz-Lys-OH) (0.52 mmol) and MSTFA 
(300 µL, 1.6 mmol) were suspended in CH2Cl2 (5 mL) and refluxed until a clear 
solution was obtained. The solution was cooled to room temperature and the 
carbonate 97a, 97b or 97c (1.0 mmol), pyridine (200 µL, 2.6 mmol) and 
triethylamine (360 µL, 2.6 mmol) were added, and the resulting mixture was stirred 
for 3 hours. Then, CH3OH (3 mL) was added to the mixture and the reaction was 
stirred for an additional 30 min. The solvent was removed in vacuo, the resulting 
crude was dissolved in CH2Cl2 (20 mL) and washed with 2 M HCl (2 × 5 mL). The 
organic layer was dried over Na2SO4 and concentrated in vacuo. The product was 
purified by flash column chromatography (9:1, CH2Cl2/CH3OH with 1% AcOH) to 













Synthesis of Fmoc-Lys(VeZ-0)-OH (97a) 
 
 
White solid. Yield: 89% (252 mg).  
Rf 0.50 (9:1, CH2Cl2/CH3OH).  
1H NMR (500 MHz, DMSO-d6
 ): δ/ppm 7.89 (d, J = 7.6 Hz, 2H), 7.71 (d, J = 7.4 Hz, 
2H), 7.41 (t, J = 7.4 Hz, 2H), 7.36 – 7.30 (m, 4H), 7.20 (t, J = 5.9 Hz, 1H), 7.06 – 
7.01 (m, 2H), 6.85 (dd, J = 13.6, 6.0, 1H), 4.95 (s, 2H), 4.72 (dd, J = 13.5, 1.6 Hz, 
1H), 4.47 (dd, J = 6.1, 1.4 Hz, 1H), 4.30 – 4.19 (m, 3H), 3.85 (m, 1H), 3.00 – 2.92 
(m, 2H), 1.73 – 1.53 (m, 2H), 1.43 – 1.20 (m, 4H).  
13C{H} NMR (125 MHz, DMSO-d6): δ/ppm 174.5, 156.5, 156.5, 156.3, 148.6, 144.3, 
141.2, 132.4, 130.2, 128.1, 127.5, 125.7, 120.6, 116.9, 95.7, 66.0, 65.1, 54.6, 47.2, 
31.2, 29.5, 23.3.  
HRMS (ESI) for C31H33N2O7 [M+H]
+: calcd. 545.2282; found 545.2263.  













Synthesis of Fmoc-Lys(VeZ-1)-OH (97b) 
 
 
White solid. Yield: 82% (245 mg). 
Rf 0.55 (9:1, CH2Cl2/CH3OH).  
1H NMR (500 MHz, DMSO-d6): δ/ppm 7.89 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 7.5 Hz, 
2H), 7.42 (t, J = 7.4 Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 7.24 (t, J = 5.7 Hz, 1H), 7.07 
(d, J = 1.9 Hz, 1H), 7.01 (d, J = 8.1 Hz, 1H), 6.90 (dd, J = 8.1, 1.9 Hz, 1H), 6.70 (dd, 
J = 13.7, 6.1 Hz, 1H), 4.96 (s, 2H), 4.54 (dd, J = 13.7, 1.7 Hz, 1H), 4.35 (dd, J = 6.1, 
1.6 Hz, 1H), 4.29 – 4.21 (m, 3H), 3.87 – 3.83 (m, 1H), 3.77 (s, 3H), 3.00 – 2.95 (m, 
2H), 1.61 – 1.53 (m, 2H), 1.42 – 1.28 (m, 4H).  
13C{H} NMR (125 MHz, DMSO-d6): δ/ppm 174.0, 156.2, 156.1, 149.7, 149.6, 144.4, 
143.8, 140.7, 133.4, 127.7, 127.1, 125.3, 120.3, 120.1, 118.2, 112.7, 93.4, 65.6, 
65.0, 55.7, 53.9, 46.7, 30.5, 29.0, 22.9 . 
HRMS (ESI) for C32H34N2O8 [M+Na]
+ calcd. 597.2205; found 597.2206.  









Synthesis of Fmoc-Lys(VeZ-2)-OH (97c) 
 
 
White solid. Yield: 80% (251 mg).  
Rf 0.67 (9:1, CH2Cl2/CH3OH). 
1H NMR (600 MHz, DMSO-d6): δ/ppm 7.89 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 7.5 Hz, 
2H), 7.59 (d, J = 8.1 Hz, 1H), 7.41 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.2 Hz, 2H), 7.28 
(t, J = 5.9 Hz, 1H), 6.72 (s, 2H), 6.49 (dd, J = 13.8, 6.3 Hz, 1H), 4.96 (s, 2H), 4.29 – 
4.26 (m, 2H), 4.24 – 4.20 (m, 1H), 4.14 (dd, J = 13.8, 1.8 Hz, 1H), 4.08 (dd, J = 6.3, 
1.9 Hz, 1H), 3.93 – 3.89 (m, 1H), 3.75 (s, 6H), 3.03 – 2.96 (m, 2H), 1.72 – 1.56 (m, 
2H), 1.45 – 1.27 (m, 4H).  
13C{H} NMR (150 MHz, DMSO-d6): δ/ppm 173.9, 156.1, 156.0, 152.2, 151.6, 143.8, 
140.7, 134.4, 131.8, 127.6, 127.0, 125.2, 120.1, 105.0, 89.1, 65.6, 65.2, 55.9, 53.8, 
46.6, 30.4, 28.9, 22.9.  
HRMS (ESI) for C33H37N2O9 [M+H]
+ calcd. 605.2494; found 605.2490.  










Synthesis of Cbz-Lys(VeZ-1)-OH (97d) 
 
 
White solid. Yield: 39% (99 mg).  
Rf 0.55 (9:1, CH2Cl2/CH3OH).  
1H NMR (500 MHz, DMSO-d6): δ/ppm 7.36 – 7.34 (m, 5H), 7.22 (t, J = 5.7 Hz, 1H), 
7.07 (d, J = 1.9 Hz, 1H), 7.02 (d, J = 8.1 Hz, 1H), 6.91 (dd, J = 8.1, 1.9 Hz,1H), 6.71 
(dd, J = 13.7, 6.1 Hz, 1H), 5.01 (s, 2H), 4.96 (s, 2H), 4.54 (dd, J = 13.6, 1.7 Hz, 1H), 
4.36 (dd, J = 6.1, 1.7 Hz, 1H), 3.80 – 3.77 (m, 1H) 3.78 (s, 3H), 2.98 – 2.95 (m, 2H), 
1.70 – 1.54 (m, 2H), 1.40 – 1.27 (m, 4H).  
13C{H} NMR (125 MHz, DMSO-d6): δ/ppm 156.5, 150.1, 150.1, 144.8, 137.7, 133.9, 
128.8, 128.2, 128.1, 120.8, 118.6, 113.2, 107.6, 93.8, 65.6, 65.4, 56.1, 40.7, 40.6, 
31.8, 29.7, 23.2.  
HRMS (ESI) for C25H31N2O8 [M+H]
+ calcd. 487.2075; found 487.2063.  










5.4.2 Isolation and characterization of compound 100 
 
 
3,6-Di-2-pyridyl-1,2,4,5-tetrazine 21 (113 mg, 0.51 mmol) was dissolved in DMF (9 
mL) and sonicated for 10 min to obtain a clear solution. Compound 99b (100 mg, 
0.17 mmol) and distilled water (1 mL) were added and the reaction mixture was 
stirred for 18 hours at 60 °C. The solvent was removed in vacuo and the resulting 
mixture was purified by flash column chromatography (9:1, CH2Cl2/CH3OH with 1% 
AcOH) to give the product 100 as a white solid in 65% yield (61 mg).  
 
Rf 0.32 (9:1, CH2Cl2/CH3OH).  
1H NMR (500 MHz, DMSO-d6): δ/ppm 7.89 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 7.5 Hz, 
2H), 7.42 (t, J = 7.4 Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 7.15 (t, J = 5.7 Hz, 1H), 6.91 
(d, J = 1.8 Hz, 1H), 6.77 – 6.73 (m, 2H), 4.87 (s, 2H), 4.31 – 4.21 (m, 3H), 3.85 – 
3.82 (m, 1H), 3.74 (s, 3H), 2.98 – 2.95 (m, 2H), 1.72 – 1.56 (m, 2H), 1.42 – 1.28 (m, 
4H). 
13C{H} NMR (125 MHz, DMSO-d6): δ/ppm 174.2, 156.2, 155.8, 147.4, 146.3, 143.9, 
143.8, 140.7, 127.8, 127.6, 127.1, 125.3, 121.1, 120.1, 115.2, 112.6, 65.5, 64.9, 
55.6, 54.4, 46.7, 29.2, 22.8, 15.6. 
HRMS (ESI) for C30H32N2O8 [M+Na]
+ calcd. 571.2051; found 571.2022. 







5.4.3 1H NMR Study of VeZ deprotection 
 
Compound 99a (5 mg, 9.2 µmol) and 3,6-di-2-pyridyl-1,2,4,5-tetrazine (6.5 mg, 27 
µmol) in DMF-d7 (2.7 mL) and D2O (300 µL) were stirred at 60 °C. Aliquots (400 µL) 
of the reaction mixture were transferred into an NMR tube at time intervals (t = 0, 1, 
3, 5, 8, 10 and 24 h) and the reaction monitored by 1H NMR spectroscopy using 3-
(trimethylsilyl)-1-propanesulfonic acid sodium salt as an internal standard (δ = 0.010 
ppm). The regions of interest were integrated and compared to the internal standard 






H NMR spectrum of 99a, showing the VeZ region 4.4–7.0 ppm. The spectra 
were recorded over time (0–24 h) in DMF-d7/D2O (9:1) at 500 MHz. Conversion was 
calculated integrating the peaks corresponding to the vinyl ether protons (H1 and H2) and 




















H NMR spectrum of 99b, showing the VeZ region 4.2–6.9 ppm. The spectra 
were recorded over time (0–24 h) in DMF-d7/D2O (9:1) at 500 MHz. Conversion was 
calculated integrating the peaks corresponding to the vinyl ether protons (H1 and H2) and 



























H NMR spectrum of 99c, showing the VeZ region 4.0–6.7 ppm. The spectra 
were recorded over time (0–24 h) in DMF-d7/D2O (9:1) at 500 MHz. Conversion was 
calculated by integrating the peaks corresponding to the vinyl ether protons (H1 and H2) and 


























5.4.4 Optimization of cleavage condition of Fmoc-Lys(VeZ)-OH 97  
 
The deprotection conditions of VeZ were screened in solution using the Fmoc-
Lys(VeZ)-OH 97 (5.6 mM) and 3,6-di-2-pyridyl-1,2,4,5-tetrazine 21 (17 mM) (see 
Table 1). The crude mixtures were analyzed by RP-HPLC to detect and quantify the 
conversion of the starting material 99a, and formation of the phenolate 13 and free 
lysine using 1-naphthol as an internal standard. HPLC analysis was performed 
eluting with a gradient of H2O/CH3CN/HCO2H (95:5:0.05) to H2O/CH3CN/HCO2H 
(5:95:0.05) over 10 min, holding at 95% CH3CN for 4 min, with detection at λ = 280 
nm and by evaporative light scattering (ELSD). tR: Fmoc-Lys-OH 97: 4.19 min; 1-
naphthol: 5.72 min; phenol 100: 6.20 min; Fmoc-Lys(VeZ)-OH 99b: 7.30 min. 
 
Table 5.1. Screening of reaction conditions for VeZ deprotection.  
Entry Solvent Temp. Time Conversion  100:97 Ratio 
1 DMF 20 °C 24 h 0% – 
2 DMF 40 °C 24 h 0% – 
3 DMF 60 °C 24 h 0% – 
4 DMF/H2O (9:1) 20 °C  18 h 2% 1:0 
5 DMF/H2O (9:1) 40 °C 18 h 58% 1:0 
6 DMF/H2O (9:1) 60 °C 18 h 80% 1:0 
7 DMF/H2O (75:25) 60 °C 18 h 92% 1:1 
8 DMF/H2O (50:50) 60 °C 18 h 100% 1:1.4 
9 DMF/buffer
[a]
 (50:50) 60 °C 18 h 100% 0:1 
10 DMF/buffer
[a]
 (50:50) 40 °C (µW) 2 h 33% 2:1 
11 DMF/buffer
[a]
 (50:50) 40 °C (µW) 4 h 43% 2:1 
12 DMF/buffer
[a]
 (50:50) 60 °C (µW) 1 h 48% 1:1 
13 DMF/buffer
[a]
 (50:50) 60 °C (µW) 2 h 58% 1:3 
14 DMF/buffer
[a]
 (50:50) 60 °C (µW) 4 h 71% 1:10 
[a]








5.4.5 Stability studies of VeZ under standard SPPS conditions 
 
Stability of the VeZ protecting group was evaluated by solution assays using the 
Fmoc and Cbz protected lysines 99b and 99d (9 mM). The crude reaction mixtures 
were analyzed by RP-HPLC (ELSD and λ = 280 nm) using 1-naphthol as an 
internal standard to detect and quantify the recovered VeZ-protected (99b and 99d) 
and mono-protected lysines (Fmoc-Lys-OH and Cbz-Lys-OH). HPLC analysis was 
performed eluting with a gradient of H2O/CH3CN/HCO2H (95:5:0.05) to 
H2O/CH3CN/HCO2H (5:95:0.05) over 10 min, holding at 95% CH3CN for 4 min, with 
detection at 280 nm and by an evaporative light scattering detector. tR: Cbz-Lys-OH 
98: 2.55; Fmoc-Lys-OH 97: 4.19 min; 1-naphthol: 5.72 min; 99b: 7.31 min; 99d: 
6.35 min.  
 
Table 5.2.  Stability of the VeZ protecting group on 99b to a variety of standard SPPS 
reaction conditions. 
Entry Reagents       Temp. time Stability 
1 24 mM Oxyma, 24 mM DIC, DMF rt 3 h Stable 
2 24 mM Oxyma, 24 mM DIC, DMF 60 °C 20 min Stable 










5 2% NH2NH2 in DMF rt 3 h *Stable 
6 20% Piperidine in DMF rt 1 h *Stable 
7 TFA/TIS/H2O (95/2.5/2.5) rt 1 h Not Stable 
8 20% TFA in DCM rt 1 h 58% Decomposition 
9 2% TFA in DCM rt 3 h Stable 
10 20% HFIP in DCM  rt 3 h Stable 







5.4.6 Stability studies of Alloc and Trt under VeZ deprotection 
conditions 
 
The stabilities of the Alloc and Trt protecting groups were evaluated by solution 
assays using Fmoc-Lys(Alloc)-OH and Fmoc-Cys(Trt)-OH (9 mM) with 3,6-di-2-
pyridyl-1,2,4,5-tetrazine 21 (27 mM). The crude reaction mixtures were analyzed 
and monitored by RP-HPLC (ELDS and λ = 280 nm), using 1-naphthol as internal 
standard to detect and quantify the recovered Fmoc-Lys(Alloc)-OH or Fmoc-
Cys(Trt)-OH (HPLC analysis was performed as described above). tR: 1-naphthol: 
5.72 min; Fmoc-Lys(Alloc)-OH: 6.75 min, Fmoc-Cys(Trt)-OH: 8.97 min.  
 
Table 5.3. Stability studies of Alloc and Trt upon VeZ deprotection conditions.  
 
Entry Tetrazine 21 Solvent time Alloc Trt 
1 27 mM 50% buffer
[a]
/DMF 4 h Not Stable Stable 
2 – 50% buffer
[a]




















5.4.7 Synthesis of dipeptide 101 on solid phase   
 
 
Rink functionalization. The Fmoc-Rink-amide linker (3 mmol) was dissolved in 
DMF (0.1 M) and ethyl(hydroxyimino)cyanoacetate (oxyma, 3 mmol) was added and 
the mixture was stirred for 10 min. N,N’-Diisopropylcarbodiimide (DIC, 3 mmol) was 
added and the resulting mixture was stirred for other 2 min. The solution was added 
to the resin (1 mmol) and shaken for 3 hours. The resin was then washed with DMF 
(× 3), CH2Cl2 (× 3) and CH3OH (× 3). The coupling reaction was monitored by the 
Kaiser test.  
Fmoc deprotection. The resin was swollen in CH2Cl2 for 1 h, drained and washed 
with CH2Cl2 (× 2). A solution of 20% piperidine in DMF (300 µL) was added to the 
resin (0.02 mmol) and the reaction mixture was shaken for 10 min. The solution was 
drained and the resin was washed with DMF (× 3), CH2Cl2 (× 3) and CH3OH (× 3). 
This procedure was repeated twice.  
Amino acid coupling. (Cbz-Lys(VeZ)-OH or Fmoc-Gly-OH (0.06 mmol) were 
dissolved in DMF (0.1 M) and oxyma (0.06 mmol, 9 mg) was added and the mixture 
was stirred for 10 min. DIC (0.06 mmol, 10 µL) was then added and the resulting 
mixture was stirred for 2 min. This solution was added to the resin (0.02 mmol), pre-
swollen in CH2Cl2, and the reaction mixture was shaken for 3 hours. The solution 
was drained and the resin washed with DMF (× 3), CH2Cl2 (× 3) and CH3OH (× 3). 
All coupling reactions were monitored by the Kaiser test.  
VeZ deprotection. A solution of 3,6-di-2-pyridyl-1,2,4,5-tetrazine 21 (30 mM) in 
sodium citrate buffer (pH = 5)/DMF (1:1) was added to the resin (0.02 mmol), pre-
swollen in CH2Cl2, and the resulting mixture was heated to 60 °C for 1 h using a 
microwave peptide synthesizer (Biotage® Initiator+ SP Wave). The solution was 
drained and the resin was washed with DMF (× 3), CH2Cl2 (× 3) and CH3OH (× 3). 




Cleavage from the resin.  A solution of TFA/H2O/TIS (95:2.5:2.5) was added to the 
resin (0.3 mL/20 mg resin), pre-swollen in CH2Cl2, and the mixture was shaken for 3 
h at room temperature. The solution was removed by filtration and the resin washed 
with the cleavage mixture (100 µL). The filtrate was evaporated and the resulting 
solid was washed with cold diethyl ether.  
Characterization of dipetide 101. The crude product obtained was analyzed by 
RP-HPLC to detect and quantify the formation of the dipeptide 101 and unreacted 
Cbz-Lys-OH 98. HPLC analysis was performed eluting with H2O/CH3CN/HCO2H 
(95:5:0.05) to H2O/CH3CN/HCO2H (5:95:0.05) over 6 min, holding at 95% CH3CN 
for 3 min, with detection at λ = 254 nm and by evaporative light scattering (ELS).  
tR: Cbz-Lys-OH 98: 2.14, dipeptide 101: 4.64 min. The dipeptide 101 was isolated 
using a semi-prep RP-HPLC (HP1100) system with UV detection (collection at λ = 
254 nm), fitted with an Agilent Eclipse XDB-C18 reverse-phase column (250 × 10 
mm, 5 μm) with a flow rate 2.5 mL/min and eluting with 0.1% HCO2H in H2O (A) and 
0.1% HCO2H in CH3CN (B), with a gradient of 5 to 95% B over 30 min. tR: 4.6 min; 
purity: 99% by ELSD.  
HRMS (ESI) for C31H35N4O6 [M+H]





Figure 5.8. HPCL traces of crude reaction mixture of 101 (ELSD and at λ = 254 nm) and 








5.4.8 Epimerization study  
 
Ac-Phe-Lys(Ac)-NH2 102a and Ac-phe-Lys(Ac)-NH2 102b were synthesized on 
aminomethyl ChemMatrix resin (loading 1 mmol/g, 35–100 mesh) and functionalised 
with a Rink linker as described before. 
Amino acid couplings, VeZ deprotection and Cleavage from the resin were 
performed as described in the previous section. 
Acetylation. A solution of Ac2O/Pyridine/DMF (2:3:5) (2 mL) was added to the resin 
(100 mg, 0.1 mmol) and the reaction mixture was shaken for 5 min. The solution 
was drained and the resin was washed with DMF (× 3), CH2Cl2 (× 3) and CH3OH (× 
3). This procedure was repeated twice. 
Purification and Characterization of diasteroisomers 102a and 102b. The crude 
dipeptide 102a or 102b was analysed by RP-HPLC and LCMS to detect and 
quantify the possible formation of any diastereoisomers. HPLC chromatogram was 
obtained using a semi-prep RP-HPLC (HP1100) system with ELS detection, fitted 
with an Agilent Eclipse XDB-C18 reverse-phase column (250 × 10 mm, 5 μm) with a 
flow rate 2.5 mL/min and eluting with 0.1% HCO2H in H2O (A) and 0.1% HCO2H in 
CH3CN (B), with a gradient of 5 to 60% B over 60 min. (See Figure 4.8, Chapter 4) 
 tR: 102a: 29.78, 102b: 30.30 min. 
LRMS for C19H29N4O4  [M+H]
+ calcd. 377.46; found 377.3 (102a), 377.2 (102b).  
HRMS (ESI) for C19H28N4O4 [M+Na]







5.4.9 Synthesis of cyclic peptides MT-II 103 and BAD BH3 104 
 
Cyclic peptides MT-II 103 (Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2) and BAD BH3 
104 (Ac-1Nal-Arg-c[Lys-Nle-Ala-Asp-Asp]-Phe-NH2) were synthesized on 
aminomethyl ChemMatrix resin (loading 1 mmol/g, 35–100 mesh). The resin was 
functionalized using 4-[(2,4-dimethoxyphenyl)-(Fmoc-amino)methyl]phenoxyacetic 
acid (Fmoc-Rink amide linker) as described above. The resin was pre-swollen in 
CH2Cl2 before each reaction step. 
Fmoc deprotection, Amino acid couplings, Acetylation. VeZ deprotection were 
performed as described in the previous sections. 
Phenylisopropyl ester deprotection. The 2-phenylisopropyl (2-PhiPr) ester of 
aspartic acid was removed by treating the resin (100 mg, 0.1 mmol) with 3% TFA in 
CH2Cl2 (v/v%). The reaction mixture was shaken for 6 min; the solution was drained 
and the resin was washed with DMF (× 3), CH2Cl2 (× 3) and CH3OH (× 3). This 
procedure was repeated 5 times. 
Cyclization on resin. The resin was washed with 5% DIPEA in DMF (2 × 3 min). A 
solution of PyBOP (156 mg, 3 equiv, 0.3 M), HOBt (40 mg, 3 equiv, 0.3 M) and 
DIPEA (100 µL, 6 equiv) in DMF (1 mL) were added to the resin (100 mg, 0.1 mmol) 
and the reaction mixture was shaken for 4 h. The solution was drained and the resin 
was washed with DMF (× 3), CH2Cl2 (× 3) and CH3OH (× 3). This procedure was 
repeated twice.  
Cleavage from the resin and purification. TFA/H2O/TIS (95:2.5:2.5) was added to 
the resin (1 mL/100 mg resin) and the mixture was shaken for 3 h at room 
temperature. The solution was removed by filtration and the resin was washed with 
the cleavage mixture once (500 µL). The filtrate was added dropwise to cold diethyl 
ether and the precipitate was collected by centrifugation. The resulting crude was 
washed with diethyl ether and the procedure was repeated three times. Both cyclic 
peptides were purified on a semi-preparative RP-HPLC (HP1100) system equipped 
with a UV detector (collection at 220 nm), fitted with an Agilent Eclipse XDB-C18 
reverse-phase column (250 × 10 mm, 5 μm) with a flow rate 2.5 mL/min and eluting 
with 0.1% HCO2H in H2O (A) and 0.1% HCO2H in CH3CN (B), with a gradient of 5 to 




(95:5:0.05) to H2O/CH3CN/HCO2H (5:95:0.05) over 6 min, holding at 95% CH3CN 
for 3 min, with detection by evaporative light scattering (ELSD). 
 
Table 5.4. Characterizations of cyclic peptides 103 and 107.  
Compound Maldi-TOF MS HPLC purity Yield 
 Calculated Found Detection by ELSD  
MT-II 103 1023.5 1024.7 [M+H]
+
 ˃ 99% (tR 3.0 min) 47% 
BAD BH3 104 1083.3 1084.5 [M+H]
+




Figure 5.9. HPLC chromatograms of crude mixture and the pure compound MT-II 103 
before and after purification by semi-preparative HPLC (A) and analytical chromatograms 





Figure 5.10. MALDI-TOF spectrum of MT-II 103. 
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